Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 1 of 169   
  
 
Protocol Title: Evaluation of Visual Acuity with a Reusable Toric Multifocal Contact [CONTACT_93820]: CR -6383  
Version: 4.0  
 
Date: [ADDRESS_103782] Articles: Bausch + Lomb Ultra® Multifocal for Astigmatism  
 
Key Words: Presby[CONTACT_19555], Multifocal, Astigmatism, Daily Wear, Dispensing, samfilcon A, 
logMAR visual acuity  
 
Statement of Compliance to protocol, GCP and applicable regulatory guidelines:  
This t rial will be conducted in compliance with the protocol, ISO [ZIP_CODE] :2020,1 the 
International Conference on Harmonization Good Clinical Practice E6 (ICH -GCP) ,2 the 
Declaration of Helsinki,3 and all applicable regulatory requirements.  
 
Confidentiality Statement:  
This document contains confidential information, which should not be copi[INVESTIGATOR_530], referred to, 
released  or published  without  written  approval  from  Johnson  & Johns on Vision  Care,  Inc. The 
information  may not be disclosed  to others  except  to the extent  necessary  to obtain  Institutional 
Review Board/Independent Ethics Committee approval and informed consent, or as required 
by [CONTACT_19543], Federal and State Laws, as applicable. Persons to whom this information is 
disclosed must be informed that this information is privilege d and confidential and that it 
should not be further disclosed without the written permission of [COMPANY_012] Vision 
Care, Inc. Any supplemental information that may be added to this document is also 
confidential and proprietary to [COMPANY_012] V ision Care, Inc. and must be kept in 
confidence in the same manner as the contents of this  document.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.[ADDRESS_103783] Article  Allocation  ................................ ................................ .............................  21 
5.2. Masking  ................................ ................................ ................................ ....................  21 
5.3. Procedures for Maintaining and Breaking  the Masking  ................................ ...........  21 
6. STUDY INTERVENTION  ................................ ................................ .............................  22 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.[ADDRESS_103784] Articles ................................ ................................ ............................  22 
6.2. Ancillary  Supplies/Products  ................................ ................................ .....................  [ADDRESS_103785] Articles  ................................ ................................ ................  24 
7. STUDY  EVALUATIONS  ................................ ................................ ..............................  25 
7.1. Time and  Event Schedule  ................................ ................................ .........................  25 
7.2. Detailed  Study Procedures  ................................ ................................ .......................  26 
VISIT  1 ................................ ................................ ................................ ...........................  26 
VISIT  2 ................................ ................................ ................................ ...........................  34 
VISIT  3 ................................ ................................ ................................ ...........................  40 
VISIT  4 ................................ ................................ ................................ ...........................  44 
FINAL EVALUATION  ................................ ................................ ................................ .. 46 
7.3. Unschedu led Visits  ................................ ................................ ................................ ... 47 
7.4. Laboratory  Procedures  ................................ ................................ .............................  49 
8. SUBJECTS  COMPLETION/WITHDRAWAL  ................................ ..............................  49 
8.1. Completion  Criteria  ................................ ................................ ................................ .. 49 
8.2. Withdrawal/Discontinuation from  the Study  ................................ ...........................  50 
9. PRE-STUDY AND  CONCOMITANT  INTERVENTION/MEDICATION  .................  [ADDRESS_103786]  QUALITY  COMPLAINTS  ..............  53 
13. ADVERSE  EVENTS  ................................ ................................ ................................ ... 54 
13.1. Definitions  and Classifications  ................................ ................................ .............  54 
13.2. Assessing  Adverse  Events  ................................ ................................ ....................  56 
13.2.1.  Causality  Assessment  ................................ ................................ ....................  57 
13.2.2.  Severity  Assessment  ................................ ................................ ......................  57 
13.3. Documentation and Follow -Up of  Adverse  Events  ................................ ..............  57 
13.4. Reporting  Adverse  Events  ................................ ................................ ....................  59 
13.4.1.  Reporting Adverse Events  to Sponsor  ................................ ..........................  59 
13.4.2.  Reporting  Adverse  Events  to the Responsible  IEC/IRB  and Health  Authorities  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.[ADDRESS_103787]  KEEPI[INVESTIGATOR_1645]/ARCHIVING  ................................  62 
15.1. Electronic Case Report  Form/Data  Collection  ................................ .....................  [ADDRESS_103788]  ................................ ................................ ................................ ...... 63 
15.3. Trial Registration  on ClinicalTrials.gov  ................................ ...............................  63 
16. DATA  MANAGEMENT  ................................ ................................ .............................  63 
16.1. Access to  Source  Data/Document  ................................ ................................ ........  63 
16.2. Confidentiality  of Information  ................................ ................................ ..............  64 
16.3. Data  Quality  Assurance  ................................ ................................ ........................  64 
16.4. Data Monitoring  Committee  (DMC)  ................................ ................................ .... [ADDRESS_103789]  (IEC/IRB)  ..........  [ADDRESS_103790]  RETENTION  ................................ ................................ ................  68 
20. FINANCIAL  CONSIDERATIONS  ................................ ................................ ............  69 
21. PUBLICATION  ................................ ................................ ................................ ...........  69 
22. REFERENCES  ................................ ................................ ................................ ............  69 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 5 of 169   
 APPENDIX A: PATIENT REPORTED OUTCOMES  (STUDY  QUESTIONNAIRES)  ..... 71 
APPENDIX B: PATIENT  INSTRUCTION  GUIDE  ................................ .............................  94 
APPENDIX C: PACKAGE INSERT  (APPROVED  PRODUCT)  ................................ .........  95 
APPENDIX D: PRESBY[CONTACT_93821]  ................................ ...... 99 
APPENDIX E:  OCULAR  DOMINANCE  ................................ ................................ ...........  100 
APPENDIX F: BINOCULAR  OVER  REFRACTION  ................................ ........................  101 
APPENDIX  G: ................................ ................................ ................................ ......................  [ADDRESS_103791] REPORTED  OCULAR SYMPTOMS  ................................ .............  118 
, DETERMINATION  OF DISTANCE  SPHEROCYLINDRICAL  REFRACTIONS  
............................................................................................................................. ..................  120 
, BIOMICROSCOPY  SCALE  ................................ ................................ .............  126 
, KERATOMETRY  ................................ ................................ ..............................  132 
, DISTANCE AND NEAR VISUAL  ACUITY  EVALUATION  ........................  134 
, TORIC  FIT EVALUATION  ................................ ................................ ..............  139 
,  DISTANCE  LOGMAR  VISUAL  ACUITY  MESAUREMENT  PROCEDURE  
............................................................................................................................. ..................  144 
, VISUAL ACUITY CHART LUMINANCE AND ROOM ILLUMIN ATION 
TESTING  ................................ ................................ ................................ ..............................  148 
APPENDIX H: GUIDELINES FOR COVID -19 RISK  MITIGATION  ..............................  157 
PROTOCOL COMPLIANCE INVESTIGATOR(S)  SIGNATURE  [CONTACT_1783]  ........................  169 
 
TABLE OF CONTENTS  
Figure 1:  Study Flowchart  ................................ ................................ ................................ ...... 14 
 
TABLE OF CONTENTS  
TABLE 1:  TEST  ARTICLES  ................................ ................................ ................................ . 22 
TABLE 2:  ANCILLARY  SUPPLIES  ................................ ................................ ....................  23 
TABLE 3: TIME  AND  EVENTS  ................................ ................................ ...........................  25 
TABLE 4: DISALLOWED  SYSTEMIC  MEDICATIONS  ................................ ...................  51 
TABLE 5: EXAMPLES OF MAJOR AND MINOR  PROTOCOL  DEVIATIONS  ..............  52 
 
Table 1:  Test Articles  ................................ ................................ ................................ ..............  22 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 6 of 169   
  
Table 2:  Ancillary Supplies  ................................ ................................ ................................ .... 23 
Table 3: Time  and Events  ................................ ................................ ................................ ....... 25 
Table 4: Disallowed  systemic  medications  ................................ ................................ .............  51 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 7 of 169   
  
PROTOCOL TITLE, NUMBER, VERSION AND DATE  
Protocol Title: Evaluation of Visual Acuity with a Reusable Toric Multifocal Contact [CONTACT_93820]:  CR-6383  
Version: 4.0  
Date: 29 October 2021  
 
 
SPONSOR NAME [CONTACT_93958] & Johnson Vision Care (JJVC) 
[ADDRESS_103792] be notified by [CONTACT_93822]/site by e -mail, fax, or 
telephone within 24 hours of learning of a Serious Adverse Even t. The Medical Monitor may 
be contact[CONTACT_93823].  General  study  related  questions 
should be directed towards your assigned clinical research  associate.  
 
The Medical Monitoring Plan is maintained as a separate docume nt and included in the Trial 
Master File.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 8 of 169   
  
AUTHORIZED SIGNATURES  
The signatures  below  constitutes  the approval  of this protocol  and the attachments  and provide 
the necessary assurances that this trial will be conducted according to all stipulations of the 
protocol, including all statements regarding confidentiality, and according to local legal and 
regulatory requirements and applicable U.S. federal regul ations,4 ICH guidelines,2 ISO 
[ZIP_CODE]:2020 ,1 and the Declaration of  Helsinki.3 
 
 
Author   See Electronic Signature  [CONTACT_93959] E 
 
 
 
Clinical Operations  
Manager   See Electronic Signature  [CONTACT_93960] & Johnson Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 9 of 169   
  
CHANGE HISTORY  
 
 
Version  Originator  Description of Change(s) and Section 
Number(s) Affected  Date  
1.[ADDRESS_103793]-2019  
2.0  
 • Updated lens  powers  
• Adapted to version 11 of protocol 
template  
• Updated disallowed  medications  
• Changed lens care  solution  
• COVID -19 appendix  added  28-Jan-2021  
3.0  
 • Updated MRD  questions  
• Updated Snellen visual acuity 
wording throughout Section  7.2 
• Changed criteria for unacceptable 
toric fit in Section  7.2 28-Apr-2021  
4.0  
 • Updated to v13 of  protocol 
template  
• Increased cylinder eligibility  range  
• Included luminance range in cd/m2 
and illuminance range in lux for 
logMAR acuity testing at Visits 3 
and 4 
• Made Visit 1 biomicroscopy 
consistent with inclusion  criteria  
• Added updated lens  label  29-Oct-2021  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.[ADDRESS_103794], Jacksonville, FL [ZIP_CODE]  
Clinical Phase  Clinical trial phase: Post -market 
Design control phase: Not applicable.  
Trial Registration  This study will be registered on ClinicalTrials.gov based on 
the following: The clinical trial is evaluating a U.S. FDA - 
regulated Device Product  
Test Article  Marketed Product: Bausch + Lomb Ultra® Multifocal for 
Astigmatism contact [CONTACT_93824] A  
material.  
Wear and Replacement 
Schedules  Wear Schedule: The lenses will be used on a daily reusable 
basis for approximately five weeks (1 week trial followed by 
4 week dispense of optimized pair).  
Replacement  Schedule:  The lenses  will be replaced  at the first 
follow -up visit only.  
Objectives  Primary Objective  
The primary objective of this study is an evaluation of the 
logMAR visual performance with the study lenses after 4 
weeks of  wear.  
 
Secondary Objective 
Not applicable.  
 
Exploratory Objective 
Not applicable.  
Study Endpoints  Primary endpoints: logMAR visual acuity at distance (4 M), 
intermediate (64 cm) and near (40 cm).  
Study Design  The study is a bilateral, single -masked, single -arm, [ADDRESS_103795] 80 subjects. The subjects will be fit 
in the study lens and wear the study lenses for 5 -9 days then 
undergo  optimization  and wear  the optimized  pair for 4 weeks 
(25-31 days), with an interim follow -up visit at 2 weeks (12 -
16 days). The prima ry endpoint will be logMAR visual 
performance.  
See the flow chart at the end of the synopsis table for the 
schematic of the study visits and procedures of main 
observations ( Figure 1 ). 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.[ADDRESS_103796] satisfy all of the following criteria to 
be enrolled in the study:  
 
Inclusion Criteria following Screening 
The subject must:  
 
1. Read, understand, and sign the STATEMENT OF 
INFORMED CONSENT and receive a fully executed 
copy of the  form . 
2. Appear able and willing to adhere to the instructions set 
forth in this clinical  protocol.  
3. Be at least [ADDRESS_103797] lens wearer in both eyes (i.e. 
has worn  lenses  a minimum  of [ADDRESS_103798]  month).  
6. Be an existing wearer of a presby[CONTACT_93825] (e.g., reading spectacles over contact [CONTACT_13276], 
multifocal or monovision contact [CONTACT_13276], etc.) or respond 
positively to at least one symptom on th e “Presby[CONTACT_93826]”.  
 
Inclusion Criteria at Baseline 
The subject must:  
 
7. Have distance spherical component of refraction in the 
range of either -1.25 D to -3.75 D or +1.25 to +3.75 D in 
each eye. 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.[ADDRESS_103799]  refractive  cylinder  in the range  of -0.75 D to -1.75 D 
in each eye, with their cylinder axis  90°±25°.  
9. Have near ADD power requirement in the range  of 
+0.75 D to +2.[ADDRESS_103800] corrected distance visual acuity of 20/20-3 or 
better in each  eye. 
 
Potential subjects who meet any of the following criteria will 
be excluded from participating in the study:  
 
Exclusion Criteria following Screening 
The subject must not:  
 
1. Be curr ently pregnant or  lactating.  
2. Have any active or ongoing ocular or systemic allergies 
that may interfere with contact [CONTACT_93827].  
3. Have any active or ongoing systemic disease, 
autoimmune disease, or use of medication, which may 
interfere with contact [CONTACT_93828] r. This may include, but 
not be limited to, diabetes, hyperthyroidism, Sjögren’s 
syndrome, xerophthalmia, acne rosacea, Stevens - 
Johnson syndrome, and immunosuppressive diseases or 
any infectious diseases (e.g. hepatitis,  tuberculosis).  
4. Use systemic medications that may interfere with contact 
[CONTACT_93829]. See section 9.[ADDRESS_103801] any know n hypersensitivity or allergic reaction to 
single use preservative free rewetting drops, sodium 
fluorescein, or Biotrue® multipurpose  solution.  
7. Have any previous, or planned, ocular or intraocular 
surgery (e.g. radial keratotomy, PRK, LASIK, lid 
procedures , cataract surgery, retinal surgery,  etc.).  
8. Have a history of amblyopia or  strabismus.  
9. Have a history of herpetic  keratitis.  
10. Have a history of irregular  cornea.  
11. Have a history of pathological dry  eye. 
12. Have participated in any contact [CONTACT_93830] 14 days prior to study  enrollment.  
13. Be an employee or immediate family member of an 
employee of clinical site (e.g., Investigator, Coordinator, 
Technician).  
 
Exclusion Criteria  at Baseline  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.[ADDRESS_103802] not:  
 
14. Have clinically significant (Grade 2 or greater) corneal 
edema, corneal vascularization, corneal staining, tarsal 
abnormalities or bulbar injection, or any other corneal or 
ocular abnormalities which would contraindicate contact 
[CONTACT_13279].  
15. Have entropi[INVESTIGATOR_2394], ectropi[INVESTIGATOR_2394], chalazia, recurrent styes, 
glaucoma, history of recurrent corneal erosions.  
16. Have any current ocular infection or  inflammation.  
17. Have any current ocular abnormality that may interfere 
with contact [CONTACT_93831]/Interventions  Use of any prescription  or over-the-counter  (OTC) 
medications that may affect contact [CONTACT_93827].  
See section 9.1 for details regarding disallowed systemic 
medications.  
Measurements and 
Procedures  The key measurements are logMAR visual acuity at distance 
(4 M), intermediate (64 cm) and near (40 cm) with the study 
lenses. See Section 7.[ADDRESS_103803]  (UADE),  or any SAE  where  relationship  to study  agent 
cannot be ruled out, may result in stoppi[INVESTIGATOR_93783]. In the event of a UADE or SAE, the 
Sponsor Medical Monitor may unmask the treatment  regimen 
of subject(s) and may discuss this with the  Principal  
Investigator [INVESTIGATOR_93784].  
Ancillary Supplies/ Study - 
Specific Materials  Rewetting drops for optional use during lens wear. Biotrue 
multi -purpose solution for lens care during dispensing period 
and for worn lens storage. Lens cases will be provided for 
temporary contact [CONTACT_93832]. Stopwatches will be provided to 
the site for use during visits.  
Principal Investigator(s) 
and Study  
Institution(s)/Site(s)  A full list of Principal Investigators, clinical sites, and 
institutions is kept separately from the Study Protocol an d is 
included in the study Trial Master File.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 14 of 169   
 
Modifications 
(up to 2 attempts, 
if necessary)  Yes 
No 
Modifications  
(if necessary)  Yes 
No 
Final Evaluation  • CLUE, MRD and CLDEQ -8 Questionnaires  
• Ocular Symptoms, Subjective Acceptance, Entrance VA, Over -Refraction  
• Toric Fitting Evaluation and Lens Fit Assessment  
• logMAR Visual  Performance  
• Lens  Removal  Follow -up 3 (Visit 4)  
• Medical History and Concomitant Medication  Review  
• Wear Time and  Compliance  • CLUE, MRD and CLDEQ -8 Questionnaires  
• Ocular Symptoms, Subjective Acceptance, Entrance VA, Over -Refraction  
• Toric Fitting Evaluation and Lens Fit Assessment  
• logMAR Visual  Performance  
• Lens Removal and Temporary  Storage  
• Biomicroscopy  
• Re-insert  lenses, exit  acuity, subject  instructions.  Schedule  follow -up 25 to 31 days after Visit  2 date Follow -up 2 (Visit 3)  
• Medical  History  and Concomitant  Medication  Review  
• Wear Time and  Compliance  • Insertion of a New Pair of Study  Lenses  
• Exit Visual  Acuity,  Dispensing  Criteria,  and Subject  Instructions  
• Schedule Follow -up in 12 to 16 Days  Dispensing  
• Lens Removal and  Biomicroscopy  Lens Optimization (up to 2 attempts allowed)  
• Lens Selection (Right, Left or Both)  
• Right  Eye Lens Insertion  and Lens Damage  (if applicable)  
• Measure  Rotation  at 1 Minute  and 3 Minutes  (if applicable)  
• Left Eye Lens Insertion  and Lens Damage  (if applicable)  
• Measure  Rotation  at 1 Minute  and 3 Minutes  (if applicable)  
• Lens  Settling,  then Toric  Fit Evaluation  and Lens  Fit Assessment  
• Visual Satisfaction, Visual Acuity,  Over -Refraction  • CLUE and MRD  Questionnaire  
• Ocular  Symptoms, Subjective  Acceptance,  Entrance  Visual  Acuity,  and Over -Refraction  
• Toric  Fit Evaluation  and Lens  Fit Assessment  Follow -up 1 (Visit 2)  
• Medical History and Concomitant Medication  Review  
• Wear Time and  Compliance  Dispensing  
• Exit Visual  Acuity  
• Dispensing  Criteria,  Subject  Instructions  
• Schedule Follow -up in 5 to 9  Days   
Figure 1: Study Flowchart  
80 Subjects to Complete (45 myopes, 35 hyperopes) 
Potential Subjects Identified Based On:  
• Age: At least 40 and not greater than 70 at the time of consent  
• Habitual contact [CONTACT_93833]  
• Refractive  Spherical  Component  either -1.25D  to -3.75D  or +1.25D  to +3.75D  
• Refractive  Cylinder: -0.75D  to -1.75D  with a cylinder  axis of 90° ± 25° 
• Near Add: +0.75D  to +2.50D  
• Visual Acuity: Best corrected 20/20 -3 or better in each eye 
Informed Consent (Visit 1)  
Eligibility Criteria 
Baseline Information  
• Habitual  lens type,  modality,  and contact [CONTACT_93834].  Wear  Time  
• Baseline  CLUE,  MRD  and CLDEQ -8 Questionnaire,  Ocular  symptoms,  and Entrance  Visual  Acuity  
• Lens  Removal,  Keratometry,  Subjective  refraction,  Add Determination,  Ocular Dominance,  Add Refinement,  and 
Near Visual Acuity  
• Biomicroscopy  
Trial Fitting (Visit 1)  
• Lens  Selection  
• Right Eye Lens Insertion and Lens Damage  
• Measure  Rotation  at 1 Minute  and 3 Minutes  
• Left Eye Lens Insertion and Lens Damage  
• Measure  Rotation  at 1 Minute  and 3 Minutes  
• Lens  Settling,  then Toric  Fit Evaluation  and Lens  Fit Assessment  
• Visual Satisfaction, Visual Acuity,  Over -Refraction  
  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.[ADDRESS_103804]  
AE Adverse Event/Adverse  Experience  
BCVA  Best Corrected Visual  Acuity  
BSCVA  Best Spectacle Corrected Visual Acuity  
CFR  Code of Fed eral Regulations  
CLUE  Contact [CONTACT_93835]  
D Diopter  
DMC  Data Monitoring  Committee  
eCRF  Electronic Case Report  Form  
EDC  Electronic Data  Capture  
ETDRS  Early Treatment Diabetic Retinopathy Study  
FDA  Food and Drug  Administration  
GCP  Good Clinical  Practice  
HIPAA  Health Insurance Portability and Accountability  Act 
IB Investigator’s  Brochure  
ICF Informed Consent  Form  
ICH International Conference on Harmonization  
IDE Investigational Device  Exemption  
IEC Independent Ethics  Committee  
IRB Institutional Review  Board  
ISO International Organization for  Standardization  
ITT Intent -to-Treat  
JJVC  [COMPANY_012] Vision Care,  Inc. 
LC Limbus  Center  
LogMAR  Logarithm of Minimal Angle of Resolution 
MedDRA© Medical Dictionary for Regulatory Activities 
MOP  Manual of  Procedures  
NIH National Institutes of  Health  
OD Right Eye  
OHRP  Office for Human Research  Protections  
OHSR  Office for Human Subjects  Research  
OS Left Eye 
OU Both  Eyes  
PD Protocol  Deviation  
PHI Protected Health  Information  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.[ADDRESS_103805] Quality  Complaint  
PRO  Patient Reported  Outcome  
QA Quality  Assurance  
QC Quality  Control  
SAE  Serious Adverse Event/Serious Adverse  Experience  
SAP Statistical Analysis Plan  
SAS Statistical Analysis  System  
SD Standard  Deviation  
SOP Standard Operating  Procedure  
UADE  Unanticipated Adverse Device  Effect  
[LOCATION_003]DE  Unanticipated Serious Adverse Device  Effect  
VA Visual  Acuity  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 17 of 169   
  
1. INTRODUCTION AND  BACKGROUND  
[COMPANY_012] Visi on launched 1 -DAY ACUVUE® MOIST Multifocal in 2015 and 
ACUVUE® OASYS MULTIFOCAL in 2021. These lenses are recommended for presby[CONTACT_93836] -0.[ADDRESS_103806] greater than -0.75 D of cylinder, in one or both eyes. Currently there are a 
limited number of soft toric multifocal lenses available. This study will evaluate the visual 
acuity achieved with one of these marketed lens types (B ausch + Lomb Ultra® Multifocal for 
Astigmatism).  
 
1.1. Name [CONTACT_93961]: Bausch + Lomb Ultra® Multifocal for Astigmatism manufactured in samfilcon 
A material.  
Refer to Table 1: Test Articles in Section 6.1 of the protocol.  
 
1.2. Intended Use of Investigation al Products  
According to the package insert, the Bausch + Lomb ULTRA® (samfilcon A) Multifocal for 
Astigmatism  Contact  [CONTACT_93837] 
(myopia, hyperopia and astigmatism) and presby[CONTACT_93838]/or not -aphakic persons 
with non -diseased eyes, exhibiting astigmatism of up to 5.00 diopters (D) and require an add 
power  ranging  from  +0.75  D to +5.00  D. In this study,  a limited  range  of refractive  corrections 
(spheres, cylinders and axes) will be evaluated (see section 3.2).  
 
1.3. Summary of Findings from Nonclinical Studies  
Not applicable for studies of marketed contact [CONTACT_13276].  
 
1.4. Summary of Known Risks and Benefits to Human  Subjects  
Not applicable for st udies of marketed contact [CONTACT_13276].  
 
1.5. Relevant Literature References and Prior Clinical Data Relevant to Proposed 
Clinical  Study  
Information  about  the Bausch  + Lomb  Ultra®  Multifocal  for Astigmatism  may be found  in the 
package insert ( APPENDIX C: PACKAGE INSERT (APPROVED  PRODUCT) . 
 
2. STUDY OBJECTIVES, ENDPOINTS AND  HYPOTHESES  
 
2.1. Objectives  
Primary Objective  
The primary objective of this study is to assess the clinical performance of the study lenses 
with respect to visual acuity (logMAR) after 4 -weeks of lens wear.  
 
Secondary Objective 
Not applicable.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 18 of 169   
  
2.2. Endpoints  
Primary Endpoint  
Visual Acuity (l ogMAR)  
Multiple assessments of binocular and monocular visual acuity will be made during the  study, 
but the binocular measurements made at the [ADDRESS_103807] 
letters in bright illuminance conditions will be the primary endp oint. At distance (4 meters), 
VA is assessed  using  ETDRS  Charts;  while  near (40 cm)  and intermediate  (64 cm) assessments 
will be made using reduced Guillon -Poling charts. Visual acuity will be measured using high 
and low contrast charts in bright illuminan ce conditions. Visual acuity will also be measured 
using  high contrast  charts  in dim illuminance  conditions  created  by [CONTACT_93839].  See 
in Appendix  G for details regarding the  collection  of 
visual acuity (logMAR).  
 
Secondary Endpoint 
Not applicable.  
 
Other Exploratory Endpoint 
Not applicable.  
 
2.3. Hypotheses  
 
Primary Hypotheses  
1. After [ADDRESS_103808] distance (4 M) 
logMAR visual acuity of the test lens will be statistically better than 0.[ADDRESS_103809] intermediate 
(64 cm) logMAR visual acuity of the test lens will be statistically better than +0.17 
logMAR.  This will be determined  using  Guillon/Poling  LogMAR  acuity  testing  charts.  
 
3. After [ADDRESS_103810] near (40 cm) 
logMAR visual acuity of the test lens will be statistically better than +0.17 logMAR. 
This will be deter mined using Guillon/Poling LogMAR acuity testing  charts.  
 
3. TARGETED STUDY  POPULATION  
 
3.1. General  Characteristics  
The population  to be studied  will consist  of adapted  contact  [CONTACT_93840].  Approximately  90 eligible  subjects  ([ADDRESS_103811] -the-rule astigmatism) will be enrolled with at least [ADDRESS_103812] -0.75 D to -1.75 D of astigmatism in both eyes 
with 90°±25°  axis. 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.[ADDRESS_103813] satisfy all of the following criteria to be enrolled in the study:  
 
Inclusion Criteria following Screening 
The subject must:  
 
1. Read, understand, and sign the STATEMENT OF INFORMED CONSENT and r eceive a 
fully executed copy of the  form.  
2. Appear able and willing to adhere to the instructions set forth in this clinical  protocol.  
3. Be at least [ADDRESS_103814] lens wearer in both eyes (i.e. has worn lenses a minimum of [ADDRESS_103815] month).  
6. Be an existing  wearer  of a presby[CONTACT_93841]  (e.g.,  reading  spectacles  over 
contact [CONTACT_13276], multifocal or monovision contact [CONTACT_13276], etc.) or respond positively to at 
least one symptom on the “Presby[CONTACT_93842]”.  
 
Inclusion Criteria at Baseline 
The subject must:  
 
7. Have distance spherical component of refraction in the r ange of either -1.25 D to -3.75 D 
or +1.25 to +3.[ADDRESS_103816] refractive cylinder in the range of -0.75 D to -1.75 D in each eye, with their  cylinder 
axis 90°±25°.  
9. Have near ADD power requirement in the range of +0.75 D to +2.[ADDRESS_103817] corrected distance visual acuity of 20/20-3 or better in each  eye. 
3.3. Exclusion Criteria  
Potential subjects who meet any of the following criteria will be excluded from participating 
in the study:  
 
Exclusion Criteria following Screening 
The subject mu st not:  
 
1. Be currently pregnant or  lactating.  
2. Have any active or ongoing ocular or systemic allergies that may interfere with  contact 
[CONTACT_13279].  
3. Have any active or ongoing systemic disease, autoimmune disease, or use of  medication, 
which may interfere with contact [CONTACT_13279]. This may include, but not be limited to, 
diabetes, hyperthyroidism, Sjögren’s syndrome, xerophthalmia, acne rosacea, Stevens - 
Johnson syndrome, and immunosuppressive diseases or any infectious diseases (e.g. 
hepatitis,  tuberculosis).  
4. Use systemic  medications  that may interfere  with contact  [CONTACT_93843]. 
See section 9.1 for additional details regarding exclud ed systemic  medications.  
5. Currently use ocular medication with the exception of rewetting  drops.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.[ADDRESS_103818] any known hypersensitivity or allergic reaction to single use preservative free 
rewetting drops, sodium fluorescein, or Biotrue® multipurpos e solution.  
7. Have  any previous,  or planned,  ocular  or intraocular  surgery  (e.g. radial  keratotomy,  PRK, 
LASIK, lid procedures, cataract surgery, retinal surgery,  etc.).  
8. Have a history of amblyopia or  strabismus.  
9. Have a history of herpetic  keratitis.  
10. Have a history of irregular  cornea.  
11. Have a history of pathological dry  eye. 
12. Have  participated  in any contact  [CONTACT_93844]  14 days prior 
to study  enrollment.  
13. Be an employee or immediate family member of an employee of clinical site (e.g., 
Investigator, Coordinator,  Technician).  
 
Exclusion Criteria at Baseline 
The subject must not:  
 
14. Have clinically significant (Grade 2 or greater) corneal edema, corneal vascular ization, 
corneal staining, tarsal abnormalities or bulbar injection, or any other corneal or ocular 
abnormalities which would contraindicate contact [CONTACT_93827].  
15. Have  entropi[INVESTIGATOR_2394],  ectropi[INVESTIGATOR_2394],  chalazia,  recurrent  styes,  glaucoma,  history  of recurrent  corneal 
erosions.  
16. Have any current ocular infection or  inflammation.  
17. Have any current ocular abnormality that may interfere with contact [CONTACT_93827]  
 
3.4. Enrollment  Strategy  
Study subjects will be recruited from the Institution/clinical site’s subject database a nd/or 
utilizing Independent Ethics Committee (IEC) or Institutional Review Board (IRB) approved 
materials.  
 
4. STUDY DESIGN AND  RATIONALE  
 
4.1. Description of Study  Design  
The study is a bilateral, single -masked, single -arm, [ADDRESS_103819] 80 subjects.  
The study begins with an initial visit (Visit 1). If a subject is found to meet all el igibility 
criteria, they will be dispensed the study lens in a bilateral fashion.  
 
If the subject  is dispensed  study  lenses  at the initial  visit,  then three  follow -up visits  will occur. 
The first follow -up visit will occur approximately one week after the initial visit. If  necessary, 
the lens power may be modified at Visit 2, then a new pair of lenses with the final lens power 
will be dispensed.  The second  follow -up (Visit  3) will occur  approximately  [ADDRESS_103820] and final follow -up evaluation (Visit 4) will occur approximately 28 days after 
Visit 2.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.[ADDRESS_103821] lens Bausch + Lomb Ultra® Multifocal for Astigmatism.  This 
study design and the clinical measurements involved are similar to recent studies of a JJVC 
prototype toric multifocal lens .6,[ADDRESS_103822]  completed 
the study and the database is finalized. Otherwise, the mask should b e broken only if specific 
emergency  treatment/course  of action  would  be dictated  by [CONTACT_93845]. In such cases, the Investigator may, in an emergency, contact [CONTACT_7195]. In 
the event the mask is broken, the Sponsor  must be informed as soon as possible. The date, 
time,  and reason  for the unmasking  must  be documented  in the subject  record.  The Investigator 
is also advised not to reveal the study treatment assignment to the clinical site or Sponsor 
personnel.  
 
Subjects who have had their treatment assignment unmasked are expected to return for all 
remaining scheduled evaluations. Subjects who are  discontinued may be replaced.  
 
5.3. Procedures for Maintaining and Breaking the  Masking  
The test articles mask shall not be broken unless information concerning the lens type is 
necessary for the urgent medical treatment of a subject. The Sponsor must be notified before 
the mask is broken.  
 
When dispensing test articles, the following steps s hould be followed to maintain 
randomization codes:  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 22 of 169   
  
1. Investigator or designee (documented on the Delegation Log) will consult the lens 
fitting schedule/randomization scheme to obtain the test article assignment for that 
subject prior to  dispen sing.  
2. Investigator  or designee  will record  the subject’s  number  on the appropriate  line of the 
randomization  scheme  
3. Investigator or designee will pull the appropriate test articles from the study supply. 
All test articles that are opened, whether dispensed  (placed/fit on eye or dispensed 
outside the clinical site) or not, must be recorded on the Test Article Accountability 
Log in the “Dispensed”  section.  
 
6. STUDY  INTERVENTION  
 
6.1. Identity of Test  Articles  
The following contact [CONTACT_35498]:  
 
Table 1: Test Articles  
 
 Test Lens  
Name  [CONTACT_59268] + Lomb Ultra® Multifocal for 
Astigmatism  
Manufacturer  Bausch + Lomb  
Lens Material  Samfilcon A  
Nominal Base Curve  8.6 
Nominal Diameter  14.5 
Nominal Distance Powers (D)  -1.00 to -4.00 in 0.25D  steps,  
+1.00 to +4.00 in 0.25D  steps  
Nominal Cylinder Powers (D)  -0.75, -1.25 
Cylinder axes (º)  70, 80, 90, 100, 110  
Nominal ADD Power (D)  Low, High  
Water Content  46% 
Oxygen Permeability (Dk)  114.0  
Wear Schedule in Current Study  Daily Reusable  
Replacement Frequency  Monthly  
Packaging Form (vial, blister, etc.)  Blister  
 
Estimated number of lenses needed = 48 per SKU (90 axis) and 24 per SKU (other axes).  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 23 of 169   
  
6.2. Ancillary  Supplies/Products  
The following solutions will be used in this  study:  
 
Table 2: Ancillary Supplies  
 
  
Single -Use Preservative -Free Rewetting Solutions 
(any of these three options may be supplied)  Multipurpose 
Disinfecting and 
Storing Solution  
 
Solution 
Name/Description  Eye-Cept® 
Rewetting 
Drops  ScleralFil® 
Preservative 
Free Saline 
Solution   
LacriPure 
Saline Solution  Biotrue® 
multipurpose  
solution  
Manufacturer  Optics 
Laboratory  Bausch + 
Lomb  Menicon  Bausch + Lomb  
 
 
Preservative   
Non- 
Preserved   
Non- 
Preserved   
 
Non-Preserved  Polyquaternium 
0.0001% and 
polyaminopropyl 
biguanide 
0.[ZIP_CODE]%  
 
Lens cases which are compatible with Biotrue® multipurpose solution will be provided to 
participants for temporary storage of contact [CONTACT_93846] [ADDRESS_103823] or damaged 
in the period up to and including Visit 2 may be replaced at the discretion of the Investigator 
and/or the Sponsor.  
 
6.4. Packaging and  Labeling  
The test articles will be packa ged in blisters as the primary packaging. The test article will be 
over-labeled to mask the subject to the identity of the lens. The test articles will be in plastic 
bags as the secondary packaging form. The sample study label is shown below:  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.[ADDRESS_103824] article associated with an Adverse Event and/or a Product 
Quality Complaint must be retained and stored in a glass vial with moderate solution pending 
directions from the sponsor for potential return to JJVC.  
 
6.7. Accountability of Test  Articles  
JJVC will provide the Investigator with sufficient quantities of study a rticles and supplies to 
complete  the investigation.  The Investigator  is asked  to retain  all lens shipment  documentation 
for the test article accountability  records.  
 
Test articles must be kept in a locked storage cabinet, accessible only to those assigned by [CONTACT_93847].  The Investigator  may delegate  this activity  to authorized  study  site 
personnel  listed  on the Site Delegation  Log. All test articles  must  be accounted.  This includes:  
1. What was dispensed for the subject for trial fitting, to wear out of the office, or issued 
for the subject to replace appropriately between  visits.  
2. What was returned to the Investigator unused, including expi[INVESTIGATOR_93785].  
3. The number and re ason for unplanned  replacements.  
 
The Investigator  will collect  all unused  test articles  from  the subjects  at the end of the subject’s 
participation. Subject returned unused test articles must be separated from the clinical study 
inventory of un -dispensed test articles and must be labeled with the subject number and date 
of return. Following final reconciliation of test articles  by [CONTACT_2037], the Investigator or 
monitor will return all unused test articles to  JJVC.  

Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.[ADDRESS_103825] the study 
monitor immediately . 
 
 
7. STUDY  EVALUATIONS  
 
7.1. Time an d Event  Schedule  
 
Table 3: Time and Events  
 
Visit Information  Visit 1 
Screening, 
Baseline, 
Treatment 1 Visit 2  
Treatment  1 
Follow -up 1 Visit 3  
Treatment  1 
Follow -up 2 Visit 4  
Treatment  1 
Follow -up 3 
Time Point  Day 0  7 ± 2 days  
after Visit 1  14 ± 2  days 
after Visit  2 28 ± 3  days 
after Visit  2 
Estimated Visit Duration  2.5 hours  1.0 hours  1.0 hours  1.5 hours  
Statement of Informed 
Consent  x    
Demographics  x    
Medical History/Concomitant 
Medications/Review  x x x x 
Current Habitual Correction  x    
Habitual Contact [CONTACT_93848]  x    
Contact [CONTACT_93849]  x    
Habitual Lens Wear Time  x    
Presby[CONTACT_19557]  x    
Screening 
Inclusion/Exclusion Criteria  x    
Ocular Symptoms  x x x x 
Entrance Distance and near 
Visual Acuity  x x x x 
Lens Removal  x x x x 
Keratometry  x    
Subjective Sphero -Cylindrical 
Refraction  x    
Near ADD Determination  x    
Ocular Dominance  x    
ADD Refinement  x    
Near Visual Acuity  x    
Slit Lamp Biomicroscopy  x x x x 
Baseline Inclusion/ Exclusion  x    
Lens Selection  x x (if optimized)    
Right Lens Insertion  x x (if optimized)    
Right Lens 1 Minute and 3 
Minute Rotation  x x (if optimized)    
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 26 of 169   
  
 
Visit Information  Visit 1 
Screening, 
Baseline, 
Treatment 1 Visit 2  
Treatment  1 
Follow -up 1 Visit 3  
Treatment  1 
Follow -up 2 Visit 4  
Treatment  1 
Follow -up 3 
Time Point  Day 0  7 ± 2 days  
after Visit 1  14 ± 2  days 
after Visit  2 28 ± 3  days 
after Visit  2 
Estimated Visit Duration  2.5 hours  1.0 hours  1.0 hours  1.5 hours  
Left Lens Insertion  x x (if optimized)    
Left Lens 1 Minute and 3 
Minute Rotation  x x (if optimized)    
Lens Settling  x x (if optimized)    
Toric Fit Assessment  x x x x 
Subjective Lens Fit 
Assessment  x x  x 
Visual Satisfaction  x x (if optimized)    
Subjective Acceptance   x x x 
Study Lens Distance and Near 
Visual Acuity  x x x x 
Over Refraction and Visual 
Acuity  x x   
Lens Power Modification (if 
applicable)  x x   
Determination of Lens 
Optimization  x x   
Lens Optimization (if 
required)  x x   
Insertion of Study Lenses  x x   
Exit Snellen Distance and 
Near Visual Acuity  x x   
Dispensing Criteria  x x   
Subject Instructions  x x   
Instruction Guide  x    
Lens Dispensing  x x   
Schedule Follow -Up x x   
Compliance   x x x 
Study Lens Wear Time   x x x 
PRO (CLUE and MRD)  
Questionnaires  x x x x 
CLDEQ -8 Questionnaire  x  x x 
Binocular Over Refraction     x 
Distance, Intermediate, and 
Near ETDRS LogMAR  
Visual Acuity      
x 
Final Evaluation     x 
 
 
7.2. Detailed Study  Procedures  
 
VISIT 1  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.[ADDRESS_103826] lenses to accurately assess 
baseline PRO (CLUE and MRD) performance. If the subject is not wearing their lenses they 
must be rescheduled.  
 
Visit 1: Screening  
Step Procedure  Details   
 
1.[ADDRESS_103827] read, understand, and sign  
the Statement of Informed Consent before 
being enrolled into the study. The Principal 
Investigator [INVESTIGATOR_022]/her designee conducting 
the informed consent discussion must also 
sign the consent form.  
 
Note : The subject must be provided a signed 
copy of this doc ument.   
1.[ADDRESS_103828]’s year of birth, age, 
gender, race and ethnicity.   
1.3 Medical History and 
Concomitant 
Medications  Questions regarding the subjects’ medical 
history and concomitant medications.   
1.[ADDRESS_103829]’s habitual  
lens type and parameters.   
1.[ADDRESS_103830] 
lens type and power (number of years and 
months).  
During the past month, what is the  minimum 
number  of days per week  that the subject  has 
worn their lenses for at least [ADDRESS_103831]’s correction type (i.e. 
monovision, multifocal, sphere with readers, 
etc.).   
1.[ADDRESS_103832] be answered “yes” and all 
responses to Exclusion Criteria must be 
answered “no” for the subject to be 
considered eligible.   
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 28 of 169   
  
 
Visit 1: Screening  
Step Procedure  Details   
  
  If subject is deemed to be ineligible after  
screening, proceed to Final Evaluation and 
complete Subject Disposition. Refraction and 
Biomicroscopy forms are not required .  
 
 
Visit 1: Baseline  
Step Procedure  Details   
  
1.10 Baseline PRO  
(CLUE and MRD) 
and CLDEQ -[ADDRESS_103833] will evaluate the vision  
characteristics, comfort characteristics, 
handling characteristics, and visual symptoms  
of their habitual lenses using the PRO (CLUE 
and MRD) and CLDEQ -[ADDRESS_103834] the distance and near Snellen visual  
acuity ( OD, OS, OU) to the nearest letter with 
the subject’s habitual contact [CONTACT_93850]. 
For near measurements use the ETDRS [ADDRESS_103835] remove their habitual lenses 
and store in an approved storage solution.   
1.14 Keratometry / SimK  Keratometry/SimK will be performed OD  
and OS and the steep and flat dioptric power 
and corresponding meridians recorded.   
 
1.[ADDRESS_103836] the refraction and 
distance visual acuity (OD, O S, OU) to the 
nearest letter.  
 
Note: Best distance visual acuity with 
sphero -cylindrical refraction must be at least  
20/20-[ADDRESS_103837] to be 
eligible in the study.   
 
1.16 Near ADD 
Determination  The near reading addition will be determined  
using the binocular crossed cylinder 
technique (BCC) at [ADDRESS_103838] 
using a +1.[ADDRESS_103839]. If the results are  Appendix  
E 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 29 of 169   
  
 
Visit 1: Baseline  
Step Procedure  Details   
  
  equivocal use the sighting dominance test to  
determine the dominant eye used for the 
study.   
1.[ADDRESS_103840] the BCC result in the trial frame and 
refine the near prescription with trial lenses 
(or flippers) under binocular conditions.   
 
1.[ADDRESS_103841] the near 
visual acuity (OD, OS, OU).   
1.[ADDRESS_103842] be answered “yes” and all responses to 
Exclusion Criteria questions must be 
answered “no” for the subject to be 
considered  eligible.  
 
If subject is deemed to be ineligible after 
baseline, proceed to Final Evaluation and 
complete all  forms.   
 
Visit 1: Treatment [ADDRESS_103843] lens parameters (power and 
lot number).  Appendix  
C 
1.[ADDRESS_103844] as 
necessary.   
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 30 of 169   
  
 
  Damaged lenses will be stored in labeled vial 
with Biotrue® multipurpose solution, and 
clearly differentiated from the other worn 
lenses that will be shipped back to the 
Sponsor. Complete the Quality Product 
Complaint form.   
1.24 Timed Settling for 
Right Lens  The investigator will start a stopwatch as 
soon as the right lens is inserted.  
 
Note: All lenses in this study have a toric 
orientation mark at the 6 o’clock position. 
Rotation measurements are made relative 
to a vertical refe rence line . 
Record base nasal or base temporal rotation 
to the nearest degree.  
At one (1) minute after insertion: Record:  
1. The rotational position to the nearest 
degree  
 
At three (3) minutes after insertion: Record:  
1. The rotational position to the nearest 
degree   
1.[ADDRESS_103845] as  necessary.  
 
Damaged lenses will be stored in labeled vial 
with Biotrue® multipurpose solution, and 
clearly differentiated from the other worn 
lenses that will be shipped ba ck to the 
Sponsor. Complete the Quality Product 
Complaint form.   
1.26 Timed Settling for 
Left Lens  The investigator will start a stopwatch as 
soon as the left lens is inserted.  
 
Note: All lenses in this study have a toric 
orientation mark at the 6 o’clock position. 
Rotation measurements are made relative 
to a vertical reference line . 
Record base nasal or base temporal rotation 
to the nearest degree.  
At one (1) minute after inserti on: Record:  
1. The rotational position to the nearest 
degree   
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 31 of 169   
  
 
  At three (3) minutes after insertion: Record:  
1. The rotational position to the nearest 
degree   
1.[ADDRESS_103846]:  
• The rotational position to the nearest 
degree  
• Lens stability with  blink  
• Toric fit acceptable or unacceptable 
Toric lens fit will be unacceptable if lenses 
rotated more than 30 degrees, or lens 
stability is worse than 5 degrees  movement 
with blink. If toric fit is unacceptable, 
remove, store, and label the lenses,  and 
proceed t o final evaluation.   
 
1.29 Lens Fit Assessment  Evaluate and grade lens centration, primary 
gaze movement, upgaze movement and 
tightness (push -up test).  
 
• The subject should not proceed to wear 
the lenses if any of the following is 
observed:  
• presence of limbal exposure (appearance 
of clear cornea) in any  gaze 
• presence of edge  lift 
• presence of unacceptable movement 
(excessive or insufficient) in all three  
movement categories (primary gaze, 
upgaze, and  push -up). 
 
If either lens is deemed unacceptable, the 
subject will be discontinued from the study. 
Remove the lenses, perform a slit -lamp 
evaluation, and complete the Final  
Evaluation form.   
 
1.[ADDRESS_103847]’s vision is acceptable 
with the lenses. Allow the subject to look 
down a hallway or out of a window for 
distance vision assessments, and for them to 
read a boo k, magazine or similar for near 
vision.   
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.[ADDRESS_103848] the distance and near Snellen visual 
acuity ( OD, OS, OU) to the nearest letter with 
the study contact [CONTACT_93850].  
For near measurements use the ETDRS [ADDRESS_103849] on near vision  under  
monocular and/or binocular conditions.   
1.33 Lens Power 
Modification (if 
applicable)  If the subject reports unsatisfactory vision, 
or is unable to obtain 20/[ADDRESS_103850] reports 
satisfactory vision with the lenses a  
modification is not required however may at 
the Investigators discretion based upon their 
findings on the measured visual acuity and/or 
over- refraction.  
Note: switching to a non -multifocal lens per 
section [ADDRESS_103851] the reason(s) for lens change (select 
all that apply):  
• The settled lens rotation is such that one of 
the other available lens cylinder axis would 
be better (use LARS rule to d etermine the 
replacement lens cylinder  axis)  
• Power Modification  needed  
• Unsatisfactory  Vision  
• Other (specify  reason)  
 
If one or both lenses are modified, repeat 
steps 1.22 through 1.32 for one or both eyes 
as appropriate.  
A maximum of two lens modifications  are 
allowed.  Appendix 
C: Fitting 
Guide  
1.[ADDRESS_103852] the distance and near Snellen visual  
acuity ( OD, OS, OU) to the nearest letter with 
the study contact [CONTACT_93850].   
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 33 of 169   
  
 
  For near measurements use the ETDRS 2000  
Series Chart 1 or 2.   
1.35 Dispensing 
Criteria  The lenses may be dispensed for 5 -9 days, if 
the following criteria are met:  
• Distance Snellen acuity equal to  or 
better than 20/30  OU 
• Subject must indicate that the vision 
is acceptable.  
• Subject  must  indicate   that  the 
comfort of the lenses is  acceptable.  
• Lenses must have an acceptable  toric 
and general lens fit.   
1.[ADDRESS_103853] on the following:  
• The lenses will be worn on a daily wear 
basis.  
• After each lens removal, use a 
rub/rinse/soak lens care regimen with 
Biotrue® multipurpose solution (per 
manufacturer’s  instructions).  
• If determined necessary by [CONTACT_93851] -preserved 
rewetting drops may be dispensed to be 
used as needed f or dryness.  
• Subjects will be instructed to wear lenses 
for a minimum of 6 hours a day, every 
day during the study. One missed day of 
lens wear per week is  acceptable.  
• Subjects will be instructed to wear their 
glasses when not wearing the study 
lenses . 
• A patient instruction booklet will be 
provided.  
 
Note: In the event a lens is lost or damaged, 
the subject will return to the investigator site 
for a determination of whether the lens will  be 
replaced or if the su bject will be 
discontinued. As much as reasonably 
possible, a damaged lens should be returned 
to the investigational site and then returned  to 
the   Sponsor.    If   lens   damage   is  present,  
complete the Product Quality Complaint 
Form.  The lens will be stored  in labeled  vial  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 34 of 169   
  
 
  with Biotrue® multipurpose solution and 
returned to the  Sponsor.   
1.[ADDRESS_103854] will be scheduled to return for 
their follow -up appointment in 7±[ADDRESS_103855] present to Visit 2 wearing the study lenses.  
 
Visit 2: Treatment [ADDRESS_103856]’s medical  
history or concomitant medications from the 
previous study visit. Record any changes, and 
any adverse events.   
2.2 Wear time and 
Comfortable Wear 
time (Study Lenses)  Record the average wearing time and 
comfortable wearing time with the study 
lenses.   
2.3 Compliance  Confirm compliance with the prescribed wear  
schedule.   
2.4 PRO (CLUE and 
MRD)  
Questionnaires  The subject will respond to the Follow -Up 
PRO (CLUE and MRD).   
2.[ADDRESS_103857]’s distance and 
near vision with the lenses is acceptable.   
2.[ADDRESS_103858] the distance and near Snellen visual  
acuity ( OD, OS, OU) to the nearest letter with 
the study contact [CONTACT_93850].  
For near measurements use the ETDRS 
[ADDRESS_103859] the results. The results of the distance 
over-refraction may also be checked for the   
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 35 of 169   
  
 
Visit 2: Treatment [ADDRESS_103860] on near vision under monocular and/or  
binocular conditions.   
2.[ADDRESS_103861]:  
• The rotational position to the nearest 
degree  
• Lens stability with  blink  
• Toric fit acceptable or unacceptable 
Toric lens fit will be unacceptable if lenses 
rotated more than 30 degrees, or lens 
stability is worse than 5 degrees  movement 
with blink. If toric fit is unacceptable, 
remove, store, and label the lenses,  and 
proceed to final evaluation.   
 
2.10 Lens Fit Assessment  Evaluate and grade lens centration, primary 
gaze movement, upgaze movement and 
tightness (push -up test).  
 
• The subject should not proceed to wear 
the lenses if any of the following is 
observed:  
• presence of limbal exposure (appearance 
of clear cornea) in any  gaze 
• presence of edge  lift 
• presence of unacceptable movement 
(excessive or insufficient) in all three  
movement categories (primary gaze, 
upgaze,  and push -up). 
 
If either lens is deemed unacceptable, the 
subject will be discontinued from the study. 
Remove the lenses, perform a slit -lamp 
evaluation, and complete the Final  
Evaluation form.   
 
2.[ADDRESS_103862]’s vision is unacceptable for at 
least one distance or the Investigator 
determines that the visual acuity or over - 
refraction are not acceptable then a lens 
modifica tion must be made. If modifications 
are not needed, proceed to step 2.23.   
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 36 of 169   
  
 
Visit 2: Treatment [ADDRESS_103863] 
10 minutes of settling time between lens 
changes. Note: switching to a non -multifocal 
lens per section 5 o f the Fitting Guide is not 
an available option in this study.   
2.12 Lens Optimization (if 
required)  Select the reason(s) for lens change (select 
all that apply):  
• The settled lens rotation is such that one of 
the other available lens cylinder axis would be 
better (use LARS rule to determine the 
replacement lens cylinder  axis).  
• Power Modification  needed  
• Unsatisfactory  Vision  
• Other (specify  reason)   
2.13 Lens Selection (if 
required)  Select the lens power, based on the Fitting  
Guide for each eye needing optimization. 
Record the test lens parameters (power and 
lot number).  Appendix 
C 
2.14 Lens Insertion (if 
required)  Subjects will insert the lens themselves. If the 
lens is uncomfortable, inspect for damage and 
remove, reinsert or replace as necessary.  
 
Damaged lenses will be stored in labeled vial 
with Biotrue® multipurpose solution, and 
clearly differentiated from the other worn 
lenses that will be shipped back to the 
Sponsor. Complete the Quality Product  
Complaint form.   
2.15 Timed Settling for 
Lens (if required)  The investigator will start a stopwatch as 
soon as the lens is inserted.  
 
Note: All lenses in this study have a toric 
orientation mark at the 6 o’clock position. 
Rotation measurements are made relative 
to a vertical reference line . 
Record base nasal or base temporal rotation to 
the nearest degree.   
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 37 of 169   
  
 
Visit 2: Trea tment 1 Follow -Up 1  
Step Procedure  Details   
 
  At one (1) minute after insertion: Record:  
1. The rotational position to the nearest 
degree  
 
At three (3) minutes after insertion: Record:  
1. The rotational position to the nearest 
degree   
2.16 Lens Settling (if 
required)  Allow the study lenses to settle for a 
minimum of 15 minutes.   
2.17 Toric Fit Evaluation 
(if required)  After lens settling, record:  
• The rotational position to the nearest 
degree  
• Lens stability with  blink  
• Lens stability with eye  versions  
• Toric fit acceptable or unacceptable 
Toric lens fit will be unacceptable if lenses 
rotated more than 30 degrees, or lens 
stability is worse than 5 degrees  movement 
with blink. If toric fit is unacceptable, 
remove, store, and label the lenses,  and 
proceed to final evaluation.   
 
2.18 Lens Fit Assessment 
(if required)  Evaluate and grade lens centration, primary 
gaze movement, upgaze movement and 
tightness (push -up test).  
 
• The subject should not proceed to wear 
the lenses if any of the following is 
observed:  
• presence of limbal exposure (appearance 
of clear cornea) in any  gaze 
• presence of edge  lift 
• presence of unacceptable movement 
(excessive or insufficient) in all three  
movement categories (primary gaze, 
upgaze,  and push -up). 
 
If either lens is deemed unacceptable, the 
subject will be discontinued from the study. 
Remove the lenses, perform a slit -lamp 
evaluation, and complete the Final 
Evaluation form.   
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 38 of 169   
  
 
Visit 2: Treatment 1 Follow -Up 1  
Step Procedure  Details   
 
2.19 Determine Visual  
Satisfaction (if 
required)  Determine if the subject’s vision is acceptable  
with the lenses. Allow the subject to look 
down a hallway or out of a window for 
distance vision assessments, and for them to 
read a book, magazine or similar for near 
vision.   
2.20 Study Lens Distance 
and Near Visual 
Acuity (if required)  Record the distance and near Snellen visual 
acuity ( OD, OS, OU) to the nearest letter with 
the study contact [CONTACT_93850].  
For near measurements use the ETDRS 2000 
Series Chart 1 or 2.   
2.21 Distance Over - 
Refraction and 
Distance Visual 
Acuity (if required)  Perform a distance over -refraction OD and 
OS using loose lenses outside of the phoropter 
under ambient room illumination. The 
distance over -refraction may also be refined 
under binocular  conditions.  
Record the results. The results of the distance 
over-refraction may also be checked for the 
impact on near vision under monocular and/or 
binocular conditions.   
2.22 Additional Lens 
Power Optimization 
(if required)  If the subject reports unsatisfactory vision, 
or is unable to obtain 20/[ADDRESS_103864] reports 
satisfactory vision with the  lenses a 
modification is not required however may at 
the Investigators discretion based upon their 
findings on the measured visual acuity and/or 
over- refraction. Note: switching to a non - 
multifocal lens per section [ADDRESS_103865] the reason(s) for lens change (select 
all that apply):  
• The settled lens rotation is such that one of 
the other available lens cylinder axis would be 
better (use LARS rule to determine the 
replacement lens cylinder  axis)  
• Power Modification  needed  
• Unsatisfactory  Vision  
• Other (specify  reason)  Appendix 
C: Fitting 
Guide  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 39 of 169   
  
 
Visit 2: Treatment [ADDRESS_103866] the distance and near Snellen visual 
acuity ( OD, OS, OU) to the nearest letter with 
the study contact [CONTACT_93850].  
For near measurements use the ETDRS 2000  
Series Chart 1 or 2.   
 
2.27 Dispensing 
Criteria  The lenses will be dispensed for 12 -16 days if 
the following criteria are met:  
• Distance Snellen acuity equal to  or 
better than 20/30  OU 
• Subject must indicate that the vision 
is acceptable.  
• Subject  must  indicate   that  the 
comfort of the lenses is  acceptable.  
• Lenses must have an acceptable  toric 
and general lens fit.   
2.[ADDRESS_103867] on the following:  
• The lenses will be worn on a daily wear 
basis.  
• After each lens removal, use a 
rub/rinse/soak lens care regimen with 
Biotrue® multipurpose solution (per 
manufacturer’s  instructions).   
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 40 of 169   
  
 
Visit 2: Treatment 1 Follow -Up 1  
Step Procedure  Details   
  
  • If determined necessary by [CONTACT_93852] -preserved 
rewetting drops may be dispensed to be 
used as needed for dryness.  
• Subjects will be instructed to wear lenses 
for a minimum of 6 hours a day, every 
day during the study. One missed day of 
lens wear per week is  acceptable.  
• Subjects will be instructed to wear their 
glasses when not wearing the study  lenses . 
• Subjects will be instructed to bring their 
habitual contacts or spectacles to the next 
visit.  
 
Note: In the event a lens is lost or damaged 
after Visit 2, the subject will return to the 
investigator site for discontinuation and Final 
Evaluation. As much as  reasonably possible, 
a damaged lens should be returned to the 
investigational site and then returned to the 
Sponsor. If lens damage is present, complete 
the Product Quality Complaint Form. The 
lens will be stored in labeled vial with 
Biotrue® multipurpose  solution and  returned  
to the Sponsor.   
2.[ADDRESS_103868] will be scheduled to return for 
their follow -up appointment in 14±[ADDRESS_103869] present to Visit 3 wearing the study lenses.  
 
Visit 3: Treatment [ADDRESS_103870]’s medical  
history or concomitant medications from the 
previous study visit. Record any changes, and 
any adverse events.   
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 41 of 169   
  
 
Visit 3: Treatment 1 Follow -Up 2  
Step Procedure  Details   
 
3.2. Wear time and  
Comfortable Wear 
time (Study Lenses)  Record the average wearing time and  
comfortable wearing time with the study 
lenses.   
3.3. Compliance  Confirm compliance with the prescribed wear 
schedule.   
3.4. PRO (CLUE and 
MRD) and CLDEQ - 
[ADDRESS_103871] will respond to the Follow -Up 
PRO (CLUE and MRD) and Dry Eye 
Questionnaires.   
3.5. Subject Reported 
Ocular Symptoms  Subjects will respond to a verbal open -ended 
symptoms questionnaire.   
 
3.6. Subjective 
Acceptance  Record whether the subject’s distance and 
near vision with the lenses is acceptable.   
3.7. Entrance Distance 
and Near Visual 
Acuity  Record the distance and near Snellen visual  
acuity ( OD, OS, OU) to the nearest letter with 
the study contact [CONTACT_93850].  
For near measurements use the ETDRS 
[ADDRESS_103872] the OD and OS results and distance 
visual acuity.  
Note: No lens changes are allowed based on 
the over -refraction.  Appendix  
F 
3.9. Toric Fit Evaluation  After lens settling, record:  
• The rotational position to the nearest 
degree  
• Lens stability with  blink  
• Toric fit acceptable or unacceptable 
Toric lens fit will be unacceptable if lenses 
rotated more than 30 degrees, or lens 
stability is worse than 5 degrees  movement 
with blink. If toric fit is unacceptable, 
remove, store, and label the lenses,  and 
proceed to final evaluation.   
 
3.10.  Lens Fit Assessment  Evaluate and grade lens centration, primary 
gaze movement, upgaze movement and 
tightness (push -up test).  
 
• The subject should not proceed to wear 
the lenses if any of the following  is 
observed:   
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 42 of 169   
  
 
Visit 3: Treatment 1 Follow -Up 2  
Step Procedure  Details   
  
  • presence of limbal exposure  (appearance  
of clear cornea) in any gaze  
• presence of edge  lift 
• presence of unacceptable movement 
(excessive or insufficient) in all three  
movement categories (primary gaze, 
upgaze, and  push -up). 
 
If either lens is deemed unacceptable, the 
subject will be discontinued from the study. 
Remove the lenses, perform a slit -lamp 
evaluation, and complete the Final  
Evaluation form.   
3.11.  Visual Performance 
Distance (4 M)  
Intermediate (64 cm)  
Near (40 cm)  Visual performance will be recorded OD, OS,  
and OU for the following:  
Distance, Bright Illuminance  
ETDRS Charts 4 M-HC#1, HC#2, HC#3 and 
LC#1, LC#2 and LC#[ADDRESS_103873] Intermediate (64 cm) and 
Near (40 cm).  
Distance, Dim Illuminance (with Distance  
goggles)  
ETDRS Charts 4 M-HC#4, HC#5, HC#6  
Near, Dim Illuminance (with Near  goggles)  
Reduced Guillon -Poling charts  
High Contrast  
Intermediate (64  cm) and Near (40 cm).  
 
Note:  
• The room illuminance must be  between  
7.3 and 7.9 EV (or 400 to 600 lux)  
• Distance, HC -1 Chart luminance 
Acceptable EV Range 10.5 -10.7 (or  180 
to 210 cd/m2) 
• Guillon -Poling, Near Chart  Luminance 
Acceptable EV Range 10.8 -11.1 (or 220 
to 280 cd/m2)  
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 43 of 169   
  
 
Visit 3: Treatment 1 Follow -Up 2  
Step Procedure  Details   
 
  • Do not use the Mesopic filter for  Dim 
luminance (Dim luminance will be 
simulated by [CONTACT_19561]).   
3.12.  Lens Removal  Have the subject remove the study lenses and 
temporarily store them in a lens case with 
Biotrue® multipurpose solution.   
3.13.  Biomicroscopy  FDA Slit Lamp Classification Scale will be 
used to grade the findings and determine 
eligibility.  
 
If the clearance of the fluorescein needs to be 
expedited, preservative -free rewetting drops 
or saline may be instilled.   
 
3.14.  Insertion of Study 
Lenses  Have the subject re -insert the lenses which 
had been removed at step 3.12.   
3.15.  Exit Distance and 
Near Visual Acuity  Record the distance and near Snellen visual  
acuity ( OD, OS, OU) to the nearest letter with 
the study contact [CONTACT_93850].  
For near measurements use the ETDRS [ADDRESS_103874] on the following:  
• The lenses will be worn on a daily wear 
basis.  
• After each lens removal, use a 
rub/rinse/soak lens care regimen with 
Biotrue® multipurpose solution (per 
manufacturer’s  instructions).  
• If determined necessary by [CONTACT_93851] -preserved 
rewetting drops may be dispensed to be 
used as needed for  dryness.  
• Subjects will be instructed to wear lenses 
for a minimum of 6 hours a day, every 
day during the study. One missed day of 
lens wear per week is  acceptable.  
• Subjects will be instructed to wear their 
glasses when not wearing the study  lenses . 
• Subjects will be instructed to bring their 
habitual contacts or spectacles to the next 
visit.   
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 44 of 169   
  
 
Visit 3: Treatment 1 Follow -Up 2  
Step Procedure  Details   
  
  Note: In the event a lens is lost or damaged  
after Visit 3, the subject will return to the 
investigator site for discontinuation and Final 
Evaluation. As much as reasonably possible, 
a damaged lens should be returned to the 
investigational site and then returned to the 
Sponsor. If lens damage is present, complete 
the Product Quality Complaint Form. The 
lens will be stored in labeled vial with  
Biotrue® multipurpose solution and  returned  
to the Sponsor.   
3.17.  Schedule 
Follow -up The subject will be scheduled to return for 
their follow -up appointment which should be 
[ADDRESS_103875] present to Visit 4 wearing the study lenses.  
 
Visit 4: Treatment [ADDRESS_103876]’s medical  
history or concomitant medications from the 
previous study visit. Record any changes, and 
any adverse events.   
4.2. Wear time and 
Comfortable Wear 
time (Study Lenses)  Record the average wearing time and 
comfortable wearing time with the study 
lenses.   
4.3. Compliance  Confirm compliance with the prescribed wear 
schedule.   
4.4. PRO (CLUE and 
MRD) and CLDEQ - 
[ADDRESS_103877] will respond to the Follow -Up 
PRO (CLUE and MRD) and Dry Eye  
Questionnaires.   
4.5. Subject Reported 
Ocular Symptoms  Subjects will respond to a verbal open -ended 
symptoms questionnaire.   
 
4.6. Subjective 
Acceptance  Record whether the subject’s distance and 
near vision with the lenses is acceptable.   
4.7. Entrance Distance 
and Near Visual 
Acuity  Record the distance and near Snellen visual  
acuity ( OD, OS, OU) to the nearest letter with 
the study contact [CONTACT_93850].  
For near measurements use the ETDRS 
2000 Series Chart 1 or 2.   
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 45 of 169   
  
 
Visit 4: Treatment [ADDRESS_103878] the OD and OS results and distance 
visual acuity.  
Note: No lens changes are allowed based on 
the over -refraction.  Appendix  
F 
4.9. Toric Fit Evaluation  After lens settling, record:  
• The rotational position to the nearest 
degree  
• Lens stability with  blink  
• Toric fit acceptable or unacceptable 
Toric lens fit will be unacceptable if lenses 
rotated more than 30 degrees, or lens 
stability is worse than 5 degrees  movement 
with blink. If toric fit is unacceptable, 
remove, store, and label the lenses,  and 
proceed to final evaluation.   
 
4.10.  Lens Fit Assessment  Evaluate and grade lens centration, primary 
gaze movement, upgaze movement and 
tightness (push -up test).  
 
• The subject should not proceed to wear 
the lenses if any of the following is 
observed:  
• presence of limbal exposure (appearance 
of clear cornea) in any  gaze 
• presence of edge  lift 
• presence of unacceptable movement 
(excessive or insufficient) in all three  
movement categories (primary gaze, 
upgaze, and  push -up). 
 
If either lens is deemed unacceptable, the 
subject will be discontinued from the study. 
Remove the lenses, perform a slit -lamp 
evaluation, and complete the Final 
Evaluation form.   
 
4.11.  Visual Performance 
Distance (4M) 
Intermediate (64 cm)  
Near (40 cm)  Visual performance will be recorded OD, OS,  
and OU for the following:  
Distance, Bright Illuminance  
ETDRS Charts 4 M-HC#1, HC#2, HC#3 and 
LC#1, LC#2 and LC#3   
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 46 of 169   
  
 
Visit 4: Treatment [ADDRESS_103879] Intermediate (64 cm) and 
Near (40 cm).  
Distance, Dim Illuminance (with Distance  
goggles)  
ETDRS Charts 4 M-HC#4, HC#5, HC#6  
Near, Dim Illuminance (with Near  goggles)  
Reduced Guillon -Poling charts  
High Contrast  
Intermediate (64 cm) and Near (40 cm).  
 
Note:  
• The room illuminance must be  between  
7.3 and 7.9 EV (or 400 to 600 lux)  
• Distance, HC -1 Chart luminance 
Acceptable EV Range 10.5 -10.7 (or  180 
to 210 cd/m2) 
• Guillon -Poling, Near Chart  Luminance 
Acceptable EV Range 10.8 -11.1 (or 220 
to 280 cd/m2) 
• Do not use the Mesopic filter for  Dim 
luminance (Dim luminance will be 
simulated by [CONTACT_93853]).   
4.12.  Lens Removal  Have the subject remove the study lenses. 
Temporarily store the worn lenses until 
Biomicroscopy has been completed. If no 
adverse event or PQC was recorded, the worn  
lenses may be discarded.   
 
 
 
FINAL EVALUATION  
The final evaluation will ordinarily take place immediately following the last scheduled 
follow -up visit per the study protocol. It may also take place at any point the subject 
discontinues the study or is terminated from the study.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.[ADDRESS_103880] the refraction and 
distance visual acuity (OD, OS, OU) to the 
nearest letter.   
 
F.[ADDRESS_103881] the distance Snellen visual acuity 
(OD, OS, OU) to the nearest letter, and the 
type of visual correction being worn (habitual  
lenses, distance spectacles or unaided).   
 
 
7.3. Unscheduled  Visits  
If, during the investigation, a subject requires an unscheduled visit to the clinical site, the 
following information will be collected at a minimum:  
• Chief complaint prompting the visit. If the reaso n is an adverse event, the applicable 
eCRF for the adverse event must be completed and subject record completed as 
appropriate  
• Date and time of the visit and all procedures completed at the unscheduled  visit 
• Review of adverse event and concomitant medications  
• Documentation  of any test article  dispensed  or collected  from  the subject,  if applicable  
• Slit lamp findings (using the Slit  Lamp Classification  Scale)  
 
If the Investigator withdraws a subject from the study, the final study visit case report forms 
must  be completed  indicating  the reason(s)  why the subject  was withdrawn.  The subject  record 
must be completed documenting the date and primary reason for withdrawal and the study 
CRA notified.  
 
Any ocular and non -ocular Adverse Events that are ongoing at the time of the study visit will 
be followed by [CONTACT_737], within licensure, un til they have resolved, returned to pre - 
treatment status, stabilized, or been satisfactorily explained. If further treatment i.e., beyond 
licensure is required, the subject will be referred to the appropriate health care provider.  
 
The following informati on will be collected during an unscheduled visit.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.[ADDRESS_103882] articles. If 
the reason is other than resupply of 
previously dispensed lenses, specify the 
reason for the visit.   
U.2 Chief Complaints (if 
applicable)  Record the subject’s chief complaints for 
reasons for the unscheduled visit.   
U.3 Adverse Events and 
Concomitant 
Medications Review  
(if applicable)  Review any changes to the subject’s medical 
history or concomitant medications from the 
previous study visit. Record any changes, and  
any adverse events.   
U.4 Entrance VA (if 
applicable)  Record the distance Snellen visual acuity 
(OD, OS, OU) to the nearest letter, and the 
type of visual correction being worn (study 
lenses, habitual lenses, distance spectacles or 
unaided).   
 
U.5 Subjective Sphero - 
cylindrical 
Refraction (if 
applicable)  Perform bare -eye subjective spherocylindrical 
refraction with a phoropter (adopt the 
maximum plus to maximum visual acuity 
(MPMVA) approach and use the duo -chrome 
test for binocular balancing) a nd record the 
best corrected distance  visual acuity to the  
nearest letter (OD, OS).   
 
U.6 Slit Lamp 
Biomicroscopy (if 
applicable)  FDA Slit Lamp Classification Scale will be 
used to grade the findings. If the clearance of 
the fluorescein needs to be expedited, 
preservative -free rewetting drops may be 
instilled.   
 
U.7 Dispensing (if 
applicable)  If the subject requires additional lenses to 
complete the wear period and is eligible to do 
so, provide additional lenses per the 
dispensing instructions given in the detailed 
study procedures.   
U.8 Toric Fit 
Evaluation (if 
applicable)  After lens settling, record:  
• The rotational position to the nearest 
degree  
• Lens stability with  blink  
• Lens stability with eye  versions  
• Toric fit acceptable or unacceptable 
Toric lens fit will be unacceptable if lenses 
rotated more than 30 degrees, or lens 
stability is worse than 5 degrees  movement   
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 49 of 169   
  
 
Unscheduled Visit  
Step Procedure  Details   
 
  with blink. If toric fit is unacceptable,  
remove, store, and label the lenses, and 
proceed to final evaluation.   
U.9 Lens Fit 
Assessment (if 
applicable)  Evaluate and grade lens centration, primary 
gaze movement, upgaze movement and 
tightness (push -up test).  
 
• The subject should not proceed to wear 
the lenses if any of the following is 
observed:  
• presence of limbal exposure (appearance 
of clear cornea) in any  gaze 
• presence of edge  lift 
• presence of unacceptable movement 
(excessive or insufficient) in all three  
movement categories (primary gaze, 
upgaze, and  push -up). 
 
If either lens is deemed unacceptable, the 
subject will be discontinued from the study. 
Remove the lenses, perform a slit -lamp  
evaluation, and complete the Final 
Evaluation form.   
 
U.10  Exit Visual Acuity 
(if applicable)  Record the distance Snellen visual acuity 
(OD, OS, OU) to the nearest letter, and the 
type of visual correction being worn (study 
lenses, habitual lenses, distance spectacles or 
unaided).   
 
 
 
7.4. Laboratory  Procedures  
None  
 
8. SUBJECTS  COMPLETION/WITHDRAWAL  
 
8.1. Completion Criteria  
Subjects are considered to have completed the study if they:  
• provided informed  consent.  
• are eligible.  
• completed all  visits  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 50 of 169   
  
8.2. Withd rawal/Discontinuation from the Study  
A subject will be withdrawn from the study for any of the following reasons:  
• Subject death during the study period.  
• Subject withdrawal of consent.  
• Subject not compliant to  protocol  
• Subject lost to  follow -up. 
• Subject no longer meets eligibility criteria (e.g. the subject becomes  pregnant).  
• Subject  develops  significant  or serious  adverse  events  causing  discontinuation  of study 
lens wear.  
• Subjects who have experienced a Corneal Infiltrative Event  (CIE).  
• Investigator’s clinical judgment regarding the subject safety reasons (that it is in the 
best interest of the subject to stop  treatment).  
• Subject missed any study visit . 
• Subject not compliant with study lens wear  schedule.  
• Subject not successfully dispensed due to lack of efficacy and safety including poor 
vision, poor comfort or unacceptable  fit. 
 
For discontinued subjects, the Investigator will:  
• Complete the current visit (scheduled or  unscheduled).  
• Complete the Final Eval uation, indicating the reason that the subject was  discontinued 
from the  study.  
• Record the spherocylindrical refraction with best corrected distance visual  acuity.  
• Collect used test article(s) (worn or brought to the visit) from the subject and discard 
them, unless otherwise stated in Section  7.2. 
• Collect all unused test article(s) from the subject.  
• Make arrangements for subject care, if needed, due to their study  participation  
 
An additional subject may be enrolled if a subject discontinues from the study prematurely.  
 
In cases  where  a subject  is lost to follow -up, every  possible  effort  must  be made  to contact  [CONTACT_93854]/withdrawal.  The measures  taken  to follow 
up must be documented including two written attempts and a certified letter (or equivalent)  as 
the final  attempt.  
 
9. PRE -STUDY AND CONCOMITANT  INTERVENTION/MEDICATION  
Concomitant medications will be do cumented during screening and updated during the study. 
Disallowed medications and therapi[INVESTIGATOR_93786]. See the Exclusion criteria for specific details.  
 
9.1. Systemic  Medications  
Certain systemic medicat ions are known to have a higher likelihood to interfere with contact 
[CONTACT_13279], chiefly by [CONTACT_35509]. A summary of disallowed medications is shown  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 51 of 169   
  
in Table 4 . Subjects with a history of taking th ese medications will be allowed to enroll only 
if: 
• The medications have been taken on a continual or routine basis for at least [ADDRESS_103883] lens wear during this  time.  
Or 
• The subject  previously  used these  medications  on a temporary  basis  and has ceased  that 
medication at least 1 week prior to signing the informed  consent.  
 
Table 4: Disallowed systemic medications  
 
Class of Drug  Common Indication(s)  Common Examples  
Anticholinergics  Irritable bowel syndrome, 
Parkinson’s disease, peptic ulcer, 
cystitis, nasal congestion, cold 
symptoms, overactive bladder, 
COPD  Bentyl, Spi[INVESTIGATOR_35444], Atrovent, 
Hyosyne, Levsin, Symax 
Fastab, Symax SL, Homax SL, 
Cogentin, Transderm Scop, etc.  
Oral Phenothiazin es Antipsychotic disorders 
(schizophrenia, mania)  Compazine, Mellarill, 
Thorazine, Phenagran, etc.  
Oral/Inhaled 
Corticosteroids  Arthritis, colitis, asthma, 
bronchitis, allergic or 
inflammatory conditions  Cortisone, Prednisone, 
Hydrocortisone, Medrol, 
Kenalog, Flonase etc.  
Oral Retinoids  Seborrhea, acne  Isotretinoin, Acitretin, 
Alitretinoin, etc.  
Oral Tetracycline  Urinary Tract Infection, acne, 
chlamydia, gonorrhea  Sumycin, Achromycin V, etc.  
 
 
10. DEVIATIONS FROM THE  PROTOCOL  
Investigator will notify study sponsor upon identification of a protocol deviation. Protocol 
deviations must be reported to the sponsor within 24 hours after discovery of the protocol 
deviation. The Investigator will report deviations per IRB/IEC requireme nts. All deviations 
will be tracked, and corrective actions implemented as appropriate.  
 
If it becomes necessary for the Investigator to implement a deviation in order to eliminate an 
immediate hazard to the trial subject, the Investigator may implement the deviation 
immediately without notification to the sponsor. Within [ADDRESS_103884] notify and provide the rationale to the Sponsor and, as 
required, the IEC/IRB.  
 
If the deviation potentially impacts the safety of patient or changes the technical integrity of 
the study, then it must be reported to IEC/IRB. This is a "Major Deviation". Deviations  
that contradict the information contained in the Informed Consent/Assent forms will be 
considered Major Deviations.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.[ADDRESS_103885] on patient safety or technic al integrity of the 
study. They are often logistical in nature.  
 
Protocol waivers are prohibited.  
 
Table  lists examples of deviations that will constitute major and minor protocol deviations  for 
this study.  
 
Table 5: Examples  of major and minor protocol deviations  
 
Deviation category  Major deviation  Minor deviation  
Out-of-window visit  Visit  attended  [ADDRESS_103886] lens group develop serious expected 
(e.g., definite or probable MK) or unexpected device related adverse events, the study will be 
suspended. Upon review and consultation with IRB, DMC, and JJVC S afety Review 
committee, the study may be terminated. This potential stoppi[INVESTIGATOR_93787]  [ADDRESS_103887]  lens for 
up to 3 years with an assumed MK rate that is below 0 .2% per patient -year. The rate of 0.2% 
per patient  year is the established  rate for extended  wear  lenses  in adults,  which  was requested 
by [CONTACT_93855] a criterion  for evaluating  a contact  [CONTACT_93856] 
a pre -IDE submission. To be conservative, 200 independent patient years were used in the 
calculation.  The probability  of observing  2 cases  or more  incidents  of MK is 0.061,  and 3 cases 
or more incidents of MK is 0.007 (given an MK rate of 0.2% per patie nt year).  
 
The occurrence of one or more Unanticipated Serious Adverse Device Effect ([LOCATION_003]DE), or 
any SAE where the relationship to study agent cannot be ruled out, may result in stoppi[INVESTIGATOR_35446]. In the event of a [LOCATION_003]DE or SAE, t he Sponsor may unmask 
the treatment regimen for the subject(s) and will discuss this with the Investigator before any 
further subjects are enrolled.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 53 of 169   
  
The Sponsor will determine when a study will be stopped. The Principal Investigator [INVESTIGATOR_93788]’s results are compromised.  
 
JJVC reserves the right to terminate the study at any time for any reason. Additionally, the 
IEC/IRB reserves the rig ht to terminate the study if an unreasonable risk is determined. The 
study can be terminated by [CONTACT_079] [INVESTIGATOR_93789],  if in their opi[INVESTIGATOR_1649],  after a discussion  with JJVC,  it is determined 
that it would be unwise to continue at the clinical  site. 
 
JJVC (and the IEC/IRB and DMC, if applicable) will evaluate all adverse events. If it is 
determined that an adverse event presents an unreasonable risk, the investigation, or that part 
of the investigation presenting the risk, will be terminated as soon as possible.  
 
Should the study be terminated (either prematurely or as scheduled), the Investigator will 
notify the IEC/IRB and Regulatory Authority as required by [CONTACT_93857].  
 
12. PROCEDURE FOR HANDLING PRODUCT QUALITY  COMPLAINTS  
A Product Quality Complaint (PQC) refers to any written, electronic, or oral communication 
that alleges deficiencies related to the identity, quality, durability, reliability, safety, 
effectiveness  or performance  of test articles  after they have  been  relea sed for clinical  trial use. 
 
Potential  complaints  may come  from  a variety  of sources  including  but not limited  to subjects, 
clinical research associates (CRA), clinical operations managers (COM), medical monitors, 
and site personnel, etc. The following are not considered product quality  complaints:  
• Subject satisfaction inquiries reported via “Subjective Questionnaires ” and “Patient 
Reported Outcomes  (PRO).”  
• Clinical test articles that are stored improperly or damaged after receipt at the 
investigational site.  
• Lens replacements that occur due to  drops/fall -outs.  
• Damage deemed by [CONTACT_93858], 
and not indicative  of a quality  deficiency  (i.e. tears,  rips, etc.),  only in situations  where 
there is no deficiency alleged by [CONTACT_19578].  
 
Within [ADDRESS_103888] b e 
recorded in the EDC system, which will trigger an automatic email notification to the 
appropriate  COM/CRA  and Clinical  QA representative.  In cases  where  the EDC  system  in use 
is not configured to send automatic notifications or when an EDC system is not used, the 
COM/CRA is responsible for notifying Clinical QA upon discovery that a PQC has  occurred.  
 
Upon receipt of the EDC notification, the COM/CRA will contact [CONTACT_19568]:  
• Date the complaint was received/recorded in the EDC System (Date of Sponsor 
Awareness).  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 54 of 169   
  
• Who received the complaint.  
• Study number.  
• Clinical site information (contact [CONTACT_2300], site ID, telephone  number).  
• Lot number(s).  
• Unique Subject Identifier(s).  
• Indication of who first observed complaint (site personnel or  subject).  
• OD/OS indication, along with whether the lens was  inserted.  
• Any relate d AE number if  applicable.  
• Detailed complaint description (scheduled/unscheduled visit, wear time, symptoms, 
resolution of symptoms,  etc.).  
• Eye Care Provider objective (slit lamp) findings if  applicable.  
• Confirmation  of product  availability  for return  (and tracking  information,  if available), 
or rationale  if product  is not available  for return  
Once a complaint is received, it will be assessed by [CONTACT_19569], CRA, or trained site personnel 
to determine if it is an Adverse Event/Serious Adverse Event (AE/SAE). If the complaint 
results in an AE/SAE, the COM/CRA, or trained site personnel will follow Se ction 13 of this 
protocol.  If the AE/SAE  was potentially  the result  of a product  quality  related  deficiency,  these 
procedures also apply and will be executed in  parallel.  
 
In some cases, a PQC form may be generated in EDC by [CONTACT_35514]. In this event, the 
PQC forms will be marked “Intentionally Left Blank” or “ILB”. Justification for ILB must be 
documented.  
 
13. ADVERSE EVENTS  
 
13.1. Definitions and  Classifications  
Adverse Event (AE) – An AE is “any untoward medical occurrence, u nintended disease or 
injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users 
or other persons, whether or not related to the investigational medical device.”  
Note : This definition includes events related to the invest igational medical device or the 
comparator, and to the procedures involved. For users or other persons, this definition is 
restricted to events related to investigational medical devices .1 
 
An AE includes any condition (incl uding a pre -existing condition) that:  
1. Was not present prior to the study, but appeared or reappeared following initiation of 
the study.  
2. Was present prior to the study but worsened during the study. This would include any 
condition resulting from concomitant illnesses, reactions to concomitant medications, 
or progression of disease  states.  
Note : Pregnancy  must  be documented  as an adverse  event  and must  be reported  to the clinical 
monitor and to the Sponsor immediately upon learning of the  event.  
 
Serious Adverse Event (SAE) – An SAE is any adverse event that led to any of the following:  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 55 of 169   
  
• Death  
• Serious deterioration in  the health of the subject that resulted in any of the  following:  
• Life-threatening illness or  injury  
• Permanent or persistent impairment of a body structure or a body  function  
• Hospi[INVESTIGATOR_93790]  
• Medical or surgical in tervention to prevent life -threatening illness or injury or 
permanent impairment to a body structure or a body  function.  
• Chronic  disease  
• Foetal distress, foetal death or a congenital physical or mental impairment of birth 
defect.  
 
Diagnoses and conditions that are considered Ocular Serious Adverse Events include, but not 
limited to:  
• Microbial Keratitis  (MK)  
• Iritis (including cells in the anterior  chamber)  
• Permanent  decrease  in best spectacle  corrected  visual  acuity  equivalent  to 2 acuity  lines 
or greater  
• Central Corneal  Opacity  
• Central Corneal  Neovascularization  
• Uveitis  
• Endophthalmitis  
• Hypopyon  
• Hyphemia  
• Penetration of Bowman’s  Membrane  
• Persistent Epi[INVESTIGATOR_93791]  
• Limbal cell Damage leading to  Conjunctivalization  
 
Significant Adverse  Events – are defined as events that are symptomatic and warrant 
discontinuation (temporary or permanent) of the contact [CONTACT_93859], but 
not limited to the following:  
• Contact [CONTACT_35516]  (CLPU)  
• Significant Infiltrative Events  (SIE)  
• Superior Epi[INVESTIGATOR_32955]  (SEALs)  
• Any Temporary Loss of > 2 Lines of  BSCVA  
• Other grade 3 or higher corneal findings, such as abrasions or  edema  
• Non-contact [CONTACT_71176] - e.g. Epi[INVESTIGATOR_71155]  (EKC)  
• Asymptomatic Cornea l Scar 
• Any corneal event which necessitates temporary lens discontinuation > 2  weeks  
 
Non-Significant Adverse Events – are defined as those events that are usually asymptomatic 
and usually do not warrant discontinuation of contact [CONTACT_35517] a  reduction in  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 56 of 169   
  
wear time. However, the Investigator may choose to prescribe treatment as a precautionary 
measure.  
 
Diagnoses and conditions that are considered Ocular Non -Significant Adverse Events include, 
but not limited to the following:  
• Non-significant Infiltrative Event (NSIE)  
• Contact [CONTACT_19573][INVESTIGATOR_19534]  (CLPC)  
• Superficial Punctate Keratitis  (SPK)  
• Conjunctivitis: Bacterial, Viral,  Allergic  
• Blepharitis  
• Meibomianitis  
• Contact  [CONTACT_32984]  
• Localized Allergic  Reactions  
• Any corneal event not explicitly defined as serious or significant adverse event,  which 
necessitates temporary lens discontinuation < [ADDRESS_103889] (ADE) – An ADE is an “adverse event related to the use of an 
investigational medical device .” 
Note 1 : This definition includes adverse events resulting from insufficient or inadequate 
instructions for use, deployment, implantation, installation, or operation, or any malfunction 
of the investigational medical device.  
Note 2 : This definition inclu des any event resulting from use error or from intentional misuse 
of the investigational medical device.[ADDRESS_103890] (UADE) – A UADE is any serious adverse effect on 
health  or safety  or any life-threatening  problem  or death  caused  by, or associated  with,  the test 
article, if that effect, problem, or death was not previously identified in nature, severity, or 
degree of incidence  in the investigational plan, Investigator’s Brochure or protocol, or any 
other unanticipated serious problem associated with the test article that relates to the rights, 
safety and welfare of  subjects.  
 
13.2. Assessing Adverse  Events  
In conjunction  with the medical  monitor,  the Investigator  will evaluate  adverse  events  to ensure 
the events are categorized correctly. Elements of categorization will  include:  
• Seriousness/Classifications (see definition in sec tion 13.1). 
• Causality  or Relatedness  – i.e. the relationship  between  the test article,  study  treatment 
or study procedures and the adverse event (not related, unlikely related, possibly 
related, or related - see definition in s ection 13.2.1 ). 
• Adverse Event Severity – Adverse event severity is used to assess the degree of 
intensity of the adverse event (mild, moderate, or severe - see definition in section 
13.2). 
• Outco me – not recovered or not resolved, recovering or resolving, recovered or 
resolved with sequelae, recovered or resolved, death related to adverse event, or 
unknown.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 57 of 169   
  
• Actions Taken – none, temporarily discontinued, permanently discontinued, or  other.  
13.2.1.  Causality  Assessment  
Causality  Assessment  – A determination  of the relationship  between  an adverse  event  and the 
test article. The test article relationship for each adverse event should be determined by [CONTACT_93860]:  
• Not Related - An adverse event that is not related to the use of the test article, study 
treatment or study  procedures.  
• Unlikely Related – An adverse event for which an alternative explanation is more 
likely, e.g. concomitant treatment, concomitant disease(s), or the relationship of time 
suggests that a causal relationship is not  likely.  
• Possibly Related – An adverse event that might be due to the use of the test article, or 
to the study  treatment  or study  procedures.  An alternative  explanation,  e.g. concomitant 
treatment, concomitant disease(s), is inconclusive. The relationship in time is 
reasonable. Therefore, the causal relationship cannot be  excluded.  
• Related  – An adverse  event  that is listed  as a possible  adverse  effect  (device)  or adverse 
reaction (drug) and cannot be reasonably explained by [CONTACT_4867], e.g. 
concomitant treatment of concomitant disease(s). The relationship in time is very 
suggestive, e.g. it is confirmed by [INVESTIGATOR_5328] -challenge and  re-challenge.  
 
13.2.2.  Severity  Assessment  
Severity  Assessment  – A qualitative  assessment  of the degree  of intensity  of an adverse  event 
as determined by [CONTACT_19577]/her by [CONTACT_423]. The assessment of 
severity is made irrespective of test article, study treatment  or study procedure relationship or 
seriousness of the event and should be evaluated according to the following  scale:  
• Mild – Event is noticeable to the subject but is easily tolerated and does not interfere 
with the subject’s daily  activities.  
• Moderate – Event is bothersome, possible requiring additional therapy, and may 
interfere with the subject’s daily  activities.  
• Severe – Event is intolerable, necessitates additional therapy or alteration of therapy 
and interferes with the subject’s daily  activities.  
 
13.3. Documentation and Follow -Up of Adverse  Events  
The recording and documenting of adverse events (ocular and non -ocular) begin when the 
subjects are exposed to the test article, study treatment or study procedure. Adverse events 
reported before the use of tes t article, start of study treatment, or study procedures will be 
recorded  as medical  history.  However,  if the condition  deteriorates  at any time during  the study 
it will be recorded  and reported  as an AE. Untoward  medical  events  reported  after the subject’s 
exit from the study will be recorded as adverse events at the discretion of the  Investigator.  
 
Upon finding an adverse event, the Principal Investigator [INVESTIGATOR_93792].  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.[ADDRESS_103891]. All 
Adverse Events including local and systemic reactions not meeting the criteria for “serious 
adverse  events”  shall  be captured  on the appropriate  case report  form  or electronic  data system. 
All adverse events occurring while the subject is enrolle d in the study must be documented 
appropriately regardless of  relationship.  
 
It is the Investigator’s  responsibility  to maintain  documentation  of each reported  adverse  event. 
All adverse  events  will be followed  in accordance  with applicable  licensing  requirements.  Such 
documentation will include the  following:  
• Adverse event (diagnosis not  symptom).  
• Drawings or photographs (where appropriate) that detail the finding (e.g., size, 
location, and depth,  etc.).  
• Date the clinical site was notified.  
• Date and time of  onset.  
• Date and time of  resolution.  
• Adverse event classification, severity, and relationship to test articles, as  applicable.  
• Treatment regimen instituted (where appropriate), including concomitant medications 
prescribed, in accordance wit h applicable licensing  requirements.  
• Any referral to another health care provider if  needed.  
• Outcome, ocular damage (if  any).  
• Likely etiology.  
• Best corrected visual acuity at the discovery of the event and upon conclusion of the 
event, if the AE is related to the visual  system.  
 
Upon discovery of an AE that is deemed ‘possibly related’ or ‘related’ to the test article or 
study procedures (whethe r related to the visual system or not), an AE review form  
must be completed. Additional dated and initialed entries should be made at follow -up 
evaluations. Separate forms must be completed for each eye if the AE is bilateral.  
 
In addition,  if an infiltrat e(s) is present,  he/she  will complete  the Corneal  Infiltrate  Assessment 
eCRF. Where necessary, a culture of the corneal lesion will be collected to determine if the 
infection is microbial in nature. If cultures are collected, the date of culture collection  and 
laboratory utilized will be  recorded.  
 
Changes in the severity of an AE shall be documented to allow an assessment of the duration 
of the event at each level of intensity to be performed. Adverse events characterized as 
intermittent require documentat ion of the onset and duration of each epi[INVESTIGATOR_1865]. Changes in the 
assessment of relationship to the Test Article shall also be clearly documented.  
 
Subjects who present with an adverse event shall be followed by [CONTACT_737], within 
licensure, until all si gns and symptoms have returned to pre -treatment status, stabilized, or 
been satisfactorily resolved. If further treatment beyond licensure is required, the patient will 
be referred to the appropriate health care provider. The Investigator will use his/her clinical 
judgment as to whether a subject reporting with an adverse event will continue in the study.  If 
a subject  is discontinued  from  the study,  it will be the responsibility  of the Investigator  to 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.[ADDRESS_103892] article, study treat ment, or study procedures may be recorded as 
“ongoing” without further  follow -up. 
 
13.4. Reporting Adverse  Events  
The Investigator  will notify  the Sponsor  of an adverse  event  by e-mail,  facsimile,  or telephone 
as soon as possible and no later than 24 hours from discovery for any serious /significant 
adverse events, and 2 days from discovery for any non -significant adverse event. In addition, 
a written report will be submitted by [CONTACT_079] [INVESTIGATOR_35451]/IRB according to 
their requirements (section 13.4.2 ). The report will comment whether the adverse event was 
considered to be related to the test article, study treatment or study  procedures.  
 
13.4.1.  Reporting Adverse Events to  Sponsor  
Serious/Significant Adverse Events  
The Inves tigator will inform the sponsor of all serious/significant adverse events occurring 
during the study period as soon as possible by e -mail or telephone, but no later than 24 hours 
following discovery of the event. The Investigator is obligated to pursue and  obtain 
information  requested  by [CONTACT_93861].  All 
subjects  experiencing  a serious/significant  adverse  event  must  be followed  up and all outcomes 
must be  reported.  
 
When medically necessary, the Investigator may break the randomization code to determine 
the identity of the treatment that the subject received. The Sponsor and study monitor should 
be notified prior to unmasking the test articles.  
 
In the event of a seri ous/significant adverse event, the Investigator must:  
• Notify the Sponsor  immediately.  
• Obtain and maintain in the subject’s records all pertinent medical information and 
medical judgment for colleagues who assisted in the treatment and follow -up of the 
subject.  
• Provide the Sponsor with a complete case history which includes a statement as to  
whether the event was or was not related to the use of the test  article.  
• Notify the IEC/IRB as required by [CONTACT_6179]/IRB reporting procedure according to 
national  regulations.  
 
Unanticipated (Serious) Adverse Device Effect (UADE)  
In the event of an Unantici pated (Serious) Adverse Device Effect (UADE), the Investigator 
will submit  a report  of the UADE  to the Sponsor  and IEC/IRB  as soon  as possible,  but no later 
than [ADDRESS_103893]. This report is in addition to the 
immediate notification mentioned  above.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.[ADDRESS_103894] report the results of the 
evaluation  to FDA, the IEC/IRB and participating Investigators within [ADDRESS_103895].  
 
Non-Serious Adverse Events  
All non -serious adverse events, including non -serious adverse device effects, will be repor ted 
to the sponsor by [CONTACT_35521] 2 days from discovery.  
 
13.4.2.  Reporting Adverse Events to the Responsible IEC/IRB and Health  Authorities  
Adverse events that meet the IEC/IRB requirements for reporting must be reported within the 
IEC/IRB’s  written  guidelines.  Each  clinical  site will refer  to and follow  any guidelines  set forth 
by [CONTACT_93862]/IRB.  Each  clinical  site will refer  to and follow  any guidelines  set forth 
by [CONTACT_19582].  
 
The Sponsor will report applicable Adverse Events to the local health authorities according to 
the written guidelines, including reporting timelines.  
 
13.5. Event of Special  Intere st 
None  
 
13.6. Reporting of  Pregnancy  
Subjects reporting pregnancy (by [CONTACT_6270] -report) during the study will be discontinued after the 
event is recorded as an Adverse Event. Once discontinued, pregnant participants and their 
fetuses will not be monitored for study related purposes. Pregnant participants are not 
discontinued from contact [CONTACT_71179], but due to 
general  concerns  relating  to pregnancy  and contact  [CONTACT_19584]. Specifically,  pregnant  women  are 
discontinued  due to fluctuations  in refractive  error  and/or  visual  acuity  that occur  secondary  to 
systemic hormonal changes, and not due to unforeseen health risks to the mother or  fetus.  
 
14. STATISTICAL  METHODS  
 
14.1. General  Considerations  
Statistical Analysis will be undertaken by [CONTACT_35522].  A 
general  description  of the statistical  methods  to be implemented  in this clinical  trial is outlined 
below.  
 
All data summaries and statistical analyses will be performed using the Statistical Analysis 
System (SAS) software Version 9.4 or higher (SAS Institute, Cary, NC). Throughout the 
analysis  of data,  the results  for each subject/eye  will be used when  available  for summarization 
and statistical  analysis.  Unsche duled  visits  will be summarized  separately  and will be excluded 
from the statistical  analysis.  
 
Summary  tables  (descriptive  statistics  and/or  frequency  tables)  will be provided  for all baseline 
variables, efficacy variables and safety variables as appropriate. Continuous variables will  be 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 61 of 169   
  
summarized with descriptive statistics (n, mean, standard deviation [SD], median, minimum 
and maximum). Frequency count and percentage o f subjects or eyes within each category  will 
be provided for categorical  data.  
 
14.2. Sample Size  Justification  
This is a pi[INVESTIGATOR_93793] a marketed contact [CONTACT_93863] + 
Lomb  Ultra®  Multifocal  for Astigmatism  with respect  to objective  vision.  This is the first time 
the sponsor will be assessing this study lens; therefore, historical data is not available to 
perform  any statistical  power  calculation.  The sample  size was chosen  by [CONTACT_93864].  
 
14.3. Analysis  Populations  
 
Safety Population:  
All subjects who were administered any test article excluding subjects who drop out prior to 
administering any test article. At least one observation should be recorded.  
 
Per-Protocol Population:  
All subjects who have successfully completed all visits and did not substantially deviate from 
the protocol as determined by [CONTACT_35524] 
(Per-Protocol Population). Justification of excluding subjects with protocol deviations in the 
Per-Protocol Population set will b e documented in a memo to file.  
 
Intent -to-Treat (ITT) Population:  
All randomized subjects regardless of actual treatment and subsequent withdrawal from  study 
or deviation from protocol. At least one observation should be  recorded.  
 
14.4. Level of Statistical  Significance  
All planned analysis for this study will be conducted with an overall type I error rate of 5%.  
 
14.5. Primary  Analysis  
LogMAR Visual Acuity  
Binocula r, high luminance, high contrast visual performance on logMAR scale will be 
analyzed  using  a linear  mixed  model.  Each  model  will include  the experimental  design  factors: 
distance  (distance/intermediate/near)  as fixed  effect.  Site will be included  as random  covariate 
when appropriate. Other baseline characteristics known of importance such as age, gender 
and/or add power will be included as fixed covariates when appropriate. The covariance 
between  residual  errors  from  the same  subject  across  different  distances  will be selected  based 
on the finite -sample corrected Akaike’s Information Criterion (Keselman et al. 1998).8 
Covariance structures considered may include: Homogenous compound symmetry (CS) and 
Unstructur ed covariance structure (UN). The structure that returns the lowest Akaike 
Information  Criteria  Corrected  (AICC)  will be selected  as the structure  that best fit the data.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.[ADDRESS_103896]  and Roger  method  will be used for the calculation  of the denominator  of degrees 
of freedom.9 
 
Comparisons will be carried out using 95% confidence intervals constructed of least -square 
means (LSM) from the linear mixed models. Statistically superiority will be concluded if the 
upper limits of the confidence intervals are below the thresholds for co rresponding distances.  
 
14.6. Secondary  Analysis  
Not Applicable  
 
14.7. Other Exploratory  Analyses  
Not Applicable  
 
14.8. Interim Analysis  
An interim analysis will not be performed on this study.  
 
14.9. Procedure for Handling Missing Data and  Drop -Outs  
Missing or spurious values will not be imputed. The count of missing values will be included 
in the summary tables and listings.  
 
14.10.  Procedure for Reporting Deviations from Statistical  Plan  
The analysis will be conducted according to that specified in above s ections. There are no 
known  reasons  for which  it is planned  to deviate  from  these  analysis  methods.  If for any reason 
a change is made, the change will be documented in the study report along with a  justification 
for the  change.  
 
15. DATA HANDLING AND RECORD  KEEPI[INVESTIGATOR_1645]/ARCHIVING  
 
15.1. Electronic Case Report Form/Data Collection  
The data for this study  will be captured  on electronic  case report  forms  (eCRFs)  using  an EDC 
system (Bioclinica). An authorized data originator will enter study data int o the eCRFs using 
the EDC  system.  Data  collected  on equipment  that is not captured  in EDC  will be formatted  to 
the specification of the JJVC database manager and sent to JJVC for  analysis.  
 
The clinical  data will be recorded  on dedicated  eCRFs  specifically  designed  to match  the study 
procedures for each visit. Only specifically delegated staff can enter data on a CRF. Once 
completed, the eCRFs will be reviewed for accuracy and completeness and signed by [CONTACT_3786]. The sponsor or sponsor’s  representatives will be authorized to gain access to the 
subject recordation for the purposes of monitoring and auditing the  study.  
 
Edit checks,  electronic  queries,  and audit  trails  are built into the system  to ensure  accurate  and 
complete  data collectio n. Data  will be transmitted  from  the clinical  site to a secure  central  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 63 of 169   
  
database as forms are completed or updated, ensuring information accuracy, security, and 
confidentiality. After the final database lock, the Investigator will be provided with  Individual 
Patient  Profiles  (IPP)  including  the full audit  trail on electronic  media  in PDF format  for all of 
the study  data.  The IPP must  be retained  in the study  files as a certified  copy  of the source  data 
for the  study.  
 
The content and structure of the eCRFs are compliant with ISO14155:[ADDRESS_103897] should be available for the following:  
• subject  identification  
• eligibility  
• study  identification  
• study discussion  
• provision of and date of informed  consent  
• visit dates  
• results of safety and efficacy parameters as required by [CONTACT_93865]  
• a record of all adverse  events  
• follow -up of adverse  events  
• medical history and concomitant  medication  
• test article receipt/dispensing/return  records  
• date of study  completion  
• reason for early discontinuation of test article or withdrawal from the study, if 
applicable  
 
The subject record is the eCRF or an external record. The author of an entry in the subject 
record must be identifiable. The first point of entry is considered to  be the source record.  
 
Adverse event notes must be reviewed and initialed by [CONTACT_737].  
 
15.3. Trial Registration on  ClinicalTrials.gov  
This study will be registered on ClinicalTrials.gov based on the following: The clinical trial  is 
evaluating a U.S. FD A-regulated Device  Product.  
 
16. DATA  MANAGEMENT  
 
16.1. Access to Source  Data/Document  
The Investigator/Institution will permit trial -related monitoring, audits, IEC/IRB review and 
regulatory inspection(s) by [CONTACT_20618]/documents. Should the 
clinical site be contact[CONTACT_35527]/IRB or regulatory autho rity, JJVC must be 
contact[CONTACT_19592] 24 hours.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.[ADDRESS_103898] and therefore may disclose it as required 
to other clinical investigators and to regulatory agencies. In order to allow the use of the 
information derived from this clini cal study, the Investigator understands that he/she has an 
obligation to provide complete test results and all data developed during this study to the 
Sponsor.  
 
16.3. Data Quality  Assurance  
Steps will be taken to ensure the accuracy and reliability of data, incl ude the selection of 
qualified investigators and appropriate clinical sites and review of protocol procedures with 
the Principal Investigator. The Principal Investigator, in turn, must ensure that all Sub - 
Investigators and clinical site personnel are fami liar with the protocol and all study -specific 
procedures and have appropriate knowledge of the study article.  
 
Training on case report form completion will be provided to clinical site personnel before the 
start of the study. The Sponsor will review case r eport forms for accuracy and completeness 
remotely during the conduct of the study, during monitoring visits, and after transmission to 
data management. Any data discrepancies will be resolved with the Investigator or designee, 
as appropriate.  
 
Quality Ass urance representatives from JJVC may visit clinical sites to review data produced 
during  the study  and to access  compliance  with applicable  regulations  pertaining  to the conduct 
of clinical trials. The clinical sites will provide direct access to study -related source 
data/documents and reports for the purpose of monitoring and auditing by [CONTACT_93866].  
 
16.4. Data Monitoring Committee  (DMC)  
Not applicable.  
 
17. CLINICAL  MONITORING  
The study monitors will maintain close contact [CONTACT_35530] [INVESTIGATOR_35453]’s designated clinical site personnel. The monitor’s responsibilities will include:  
• Ensuring that the investigation is being conducted according to the proto col, any 
subsequent versions, and regulatory requirements are maintained.  
• Ensuring the rights and wellbeing of subjects are  protected.  
• Ensuring adequate resources, including facilities, laboratories, equipment, and 
qualified clinical site  personnel.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 65 of 169   
  
• Ensuring that protocol deviations are documented with corrective action plans, as 
applicable.  
• Ensuring that the clinical site has sufficient test article and  supplies.  
• Clarifying questions regarding the  study.  
• Resolving study issues or problems that may  arise.  
• Reviewing of study records and source documentation verification in accordance with 
the monitoring plan.  
 
18. ETHICAL AND REGULATORY  ASPECTS  
 
18.1. Study -Specific Design  Considerations  
Potential  subjects  will be fully informed  of the risks  and requirements  of the study  and, during 
the study,  subjects  will be given  any new information  that may affect  their decision  to continue 
participation.  Subjects  will be told that their consent  to participate  in the study  is voluntary  and 
may be withdrawn at any time with no reason given and without penalty or loss of benefits to 
which they would otherwise be entitled. Only subjects who are fully able to understand the 
risks, benefits, and potential adverse events of the study , and provide their consent  voluntarily 
will be  enrolled.  
 
18.2. Investigator  Responsibility  
The Principal Investigator [INVESTIGATOR_71157], the investigational plan, Section 4 of the ICH E6 
guidelines on Good Clinical Practice (GCP),[ADDRESS_103899] maintain 
clinical study files in accordance with Section 8 of the ICH E6 guidelines on Good Clinical 
Practice (GCP) ,[ADDRESS_103900]  (IEC/IRB)  
Before the start of the study, the Investigator (or Sponsor when applicable) will provide the 
IEC/IRB with current and complete copi[INVESTIGATOR_23747] (where applicable):  
• Final  protocol.  
• Sponsor -approved informed consent form (and any other written materials to be 
provided to the  subjects)  
• Investigator’s Brochure (or equivalent  information).  
• Sponsor -approved subject recruitment  materials.  
• Information on compensation for study -related injur ies or payment to subjects for 
participation in the  study.  
• Investigator’s curriculum vitae, clinical licenses, or equivalent information (unless  not 
required, as documented by  [CONTACT_8134]/IRB).  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 66 of 169   
  
• Information regarding funding, name [CONTACT_19618], ins titutional affiliations, other 
potential conflicts of interest, and incentives for  subjects.  
• Any other documents that the IEC/IRB requests to fulfill its  obligation.  
 
This study  will be undertaken  only after IEC/IRB  has given  full approval  of the final protocol, 
the informed consent form, applicable recruiting materials, and subject compensation 
programs, and the Sponsor has received a copy of this approval. This approval letter must be 
dated and must clearly identify the documents being  approved.  
 
During t he study, the Investigator (or Sponsor when applicable) will send the following 
documents to the IEC/IRB for their review and approval, where appropriate:  
• Protocol  revisions  
• Revision(s)  to informed  consent  form  and any other  written  materials  to be provided  to 
subjects  
• If applicable, new or revised subject recruitment materials approved by [CONTACT_16049]  
• Revisions to compensation for study -related injuries or payment to subjects for 
participation in the  study  
• Investigator’s Brochure  revisions  
• Summaries of the status of the study (at least annually or at intervals stipulated in 
guidelines of the  IEC/IRB)  
• Reports of adverse events that are serious, unanticipated, and associated with the test 
articles, according to the IRB’s requirements  
• New information tha t may adversely affect the safety of the subjects or the conduct of 
the study  
• Major protocol deviations as required by [CONTACT_6179]/IRB  
• Report of deaths of subjects under the Investigator's  care 
• Notification if a new Investigator is responsible for the study at  the clinical  site 
• Any other requirements of the  IEC/IRB  
 
For protocol  revisions  that increase  subject  risk, the revisions  and applicable  informed  consent 
form revisions must be submitted promptly to the IEC/IRB for review and approval before 
implementation of the  change(s).  
 
At least once a year, the IEC/IRB will review and reapprove this clinical study. This request 
should be documented in writing.  
 
At the end of the study, the Investigator (or Sponsor where required) will notify the IEC/IRB 
about  the study  completion.  Documentation  of this notification  must  be retained  at the clinical 
site and a copy provided to the CRO or Sponsor as  applicable.  
 
18.4. Informed  Consent  
Each  subject  or their representative,  must  give written  consent  according  to local  requirements 
after the nature  of the study  has been  fully  explained.  The consent  form  must  be signed  before 
performance of any study -related activity. The consent form that is used must be approved  by 
[CONTACT_93867] & Johnson Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 67 of 169   
  
both the Sponsor and by [CONTACT_90818]/IRB. The informed consent is in accordance with 
principles that originated in the Declaration of He lsinki,3 current ICH2 and ISO [ZIP_CODE]:[ADDRESS_103901]'s dated signature. After having obtained the 
consent, a copy of the informed consent form must be given to the  subject.  
 
Each subject for this study will complete an assent and a parent or legal guardian must give 
written  informed  consent  according  to local  requirements  after the nature  of the study  has been 
fully  explained.  The assent  and consent  forms  must  be signed  before  performance  of any study - 
related activity. The assent and consent forms that are used must be approved by [CONTACT_93868]/IRB. The assent and informed consent forms should be in 
accordance with principles that originated i n the Declaration of Helsinki ,[ADDRESS_103902] and parent and/or legal guardian the aims, methods, 
reasonably anticipated benefits, and potential hazards of the study or pre -screening, and any 
discomfort it may entail.  Subjects and parent and/or legal guardian will be informed that their 
participation is voluntary and that they may withdraw consent to participate at any time.  They 
will be informed  that choosing  not to participate  will not affect  the care the subject  will receive. 
Finally,  they will be told that the Investigator  will maintain  a subject  identification  register  for 
the purposes  of long-term follow -up if needed  and that their records  may be accessed  by [CONTACT_93869] w ithout violating the confidentiality of the 
subject, to the extent permitted by [CONTACT_6983](s) or regulations. By [CONTACT_93870], the subject is authorizing such access and agrees to be contact[CONTACT_93871].  
 
18.5. Privacy of Personal  Data  
The collection, processing and disclosure of personal data and medical information related to  
the Study Subject, and personal data related to Principal Investigator [INVESTIGATOR_93794] (e.g., name, clinic address and phone number, curriculum vitae) is subject to 
compliance with the Health Information Portability and Accountability Act (HIPAA) in the 
United  States5 and other  applicable  personal  data protection  and security  laws and regulations. 
Appropriate  measures  will be employed  to safeguard  these  data,  to maintain  the confidentiality 
of the person’s  related  health  and medical  information,  to properly  inform  the concerned  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.[ADDRESS_103903] confidence by [CONTACT_4718], 
monitors, Sponsor’s personnel and IEC/IRB. No data will be disclosed to any third party 
without the express permission of the subject concerned,  with the exception of Sponsor 
personnel (monitor, auditor), IEC/IRB and regulatory organizations in the context of their 
investigation related activities that, as part of the investigation will have access to the CRFs 
and subject  records.  
 
The collection and processing of personal data from subjects enrolled in this study will be 
limited  to those  data that are necessary  to investigate  the efficacy,  safety,  quality,  and utility  of 
the investigational product(s) used in this  study.  
 
These  data must  be collec ted and processed  with adequate  precautions  to ensure  confidentiality 
and compliance with applicable data privacy protection laws and  regulations.  
The Sponsor ensures that the personal data will be:  
• processed fairly and lawfully.  
• collected for specified, explicit, and legitimate purposes and not further processed in  a 
way incompatible with these  purposes.  
• adequate, relevant, and not excessive in relation to said  purposes.  
• accurate and, where necessary , kept current.  
 
Explicit consent for the processing of personal data will be obtained from the participating 
subject before collection of data. Such consent should also address the transfer of the data to 
other entities and to other countries.  
 
The subjec t has the right  to request  through  the Investigator  access  to his personal  data and the 
right to request rectification of any data that are not correct or complete. Reasonable steps 
should  be taken  to respond  to such a request,  taking  into consideration  the nature  of the request, 
the conditions of the study, and the applicable laws and  regulations.  
 
Appropriate technical and organizational measures to protect the personal data against 
unauthorized disclosures or access, accidental or unlawfu l destruction, or accidental loss or 
alteration must be put in place. Sponsor personnel whose responsibilities require access to 
personal data agree to keep the identity of study subjects confidential.  
 
19. STUDY RECORD  RETENTION  
In compliance with the ICH/GCP  guidelines,2 the Investigator/Institution will maintain all 
CRFs and all subject records that support the data collected from each subject, as well as all 
study documents as specified in ICH/GCP2 and all study documents as specified by [CONTACT_93872](s).  The Investigator/Institution  will take measures  to prevent 
accidental or premature destruction of these  documents.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.[ADDRESS_103904] two (2) years after the last approval of a 
marketing application in an ICH region and until there are no pending or contemplated 
marketing applications in an ICH region or until at least two (2) years hav e elapsed since the 
formal discontinuation of clinical development of the investigational product. These 
documents will be retained for a longer period if required by [CONTACT_35533]. It is the responsibi lity of the Sponsor to inform the 
Investigator/Institution as to when these documents no longer need to be retained.  
 
If the responsible Investigator retires, relocates, or for other reasons withdraws from the 
responsibility of keepi[INVESTIGATOR_8090], c ustody must be transferred to a person who will 
accept the responsibility. The Sponsor must be notified in writing of the name [CONTACT_19619]. Under no circumstance shall the Investigator relocate or dispose of any 
study documents before having obtained written approval from the Sponsor.  
 
If it becomes necessary for the Sponsor or the appropriate regulatory authority to review any 
documentation relating to this study, the Investigator must permit access to such reports.  
If the Investigator has a question regarding retention of study records, he/she should contact 
[CONTACT_19599].  
 
20. FINANCIAL  CONSIDERATIONS  
Remuneration  for study  services  and expenses  will be set forth  in detail  in the Clinical  Research 
Agreement. The Research Agreeme nt will be signed by [CONTACT_079] [INVESTIGATOR_1238] a JJVC 
management representative prior to study  initiation.  
 
JJVC reserves the right to withhold remuneration for costs associated with protocol violations 
such as:  
• Continuing an ineligible subject in the  study.  
• Scheduling a study visit outside the subject’s acceptable visit  range.  
 
JJVC reserves the right to withhold final remuneration until all study related activities have 
been completed, such as:  
• Query  resolution.  
• Case Report Form  signature.  
• Completion of any follow -up action  items.  
 
21. PUBLICATION  
There is no plan to publish the out come of this investigation.  
 
22. REFERENCES  
1. ISO [ZIP_CODE]:2020: Clinical Investigation of Medical Devices for Human Subjects — 
Good Clinical Practice. Available at:  https://www.iso.org/standard/[ZIP_CODE].html  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 70 of 169   
  
2. International Conference o n Harmonization Good Clinical Practice E6 (ICH -GCP). 
Available at: http://www.ich.org/products/guidelines/efficacy/article/efficacy - 
guidelines.html  
3. Declaration of Helsink i - Ethical principles for Medical Research Involving  Human 
Subjects. Available at: htt ps://www.wma.net/poli cies-post/wma -declaration -of- 
helsinki -ethical -principles -for-medical -research -involving -human -subjects/  
4. [LOCATION_002] (US) Code of Federal Regulations (CFR). Available at: 
https://www.gpo.gov/fdsys/browse/collectionCfr .action?collectionCode=CFR  
5. Health  Information Portability and Accountability Act (HIPAA). Available  at: 
https://www.hhs.gov/hip aa/for -professionals/privacy/index.html  
6. Franklin  R. Clinical Study Protocol. Pi[INVESTIGATOR_93795] a Silicone  Hydrogel 
Daily Disposable Toric Multifocal Contact [CONTACT_19550]. August 06,  2020.  
7. Franklin  R. Clinical Study Protocol. Evaluation of Silicone Hydrogel 
Multifocal Toric Contact [CONTACT_93873] a Hyperopic Population. January 11,  2021.  
8. Keselman HJ, Algina J, Kowalchuk RK, Wolfinger RD. A Comparison of Two 
Approaches  for Selecting  Covariance  Structures  in the Analysis  of Repeated  Measures. 
Communications in Statistics —Simulation and Computation.  1998;27(3):[ADDRESS_103905] MG, Roger JH. Small Sample Inference for Fixed Effects from Restricted 
Maximum Likelihood. Biometrics . 1997;53:983 -997. 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 71 of 169   
  
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES)  
Protocol 6383  [COMPANY_012] Vision Care, Inc. Confidential  1 
Page 72 of 169   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CR-6383, v 4.0   
PRO SPECIFICATIO   
3 Final 2021 -04-28 JJVC CONFIDENTIAL  
Protocol 6383  [COMPANY_012] Vision Care, Inc. Confidential  2 
Page 73 of 169   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CR-6383, v 4.0   
PRO  SPECIFICATIO  3 Final  2021 -04-28 JJVC CONFIDENTIAL  
Protocol 6383  [COMPANY_012] Vision Care, Inc. Confidential  3 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
PRO SPECIFICATIO  
Page 74 of 169  3 Final 2021 -04-28  
  
Protocol 6383  [COMPANY_012] Vision Care, Inc. Confidential  4 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
PRO SPECIFICATIO  
Page 75 of 169  3 Final 2021 -04-28  
  
Protocol 6383  [COMPANY_012] Vision Care, Inc. Confidential  5 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
PRO SPECIFICATIO  
Page 76 of 169  3 Final 2021 -04-28  
  
Protocol 6383  [COMPANY_012] Vision Care, Inc. Confidential  77 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
PRO SPECIFICATIO  
Page 77 of 169  3 Final 2021 -04-28  
  
Protocol 6383  [COMPANY_012] Vision Care, Inc. Confidential  78 
PRO SPECIFICATIO  
Page 78 of 169  3 Final 2021 -04-28  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CR-6383, v 4.0  
Protocol 6383  [COMPANY_012] Vision Care, Inc. Confidential  8 
PRO SPECIFICATIO  
Page 79 of 169  3 Final 2021 -04-28  
  
Protocol 6383  [COMPANY_012] Vision Care, Inc. Confidential  9 
PRO SPECIFICATIO  
Page 80 of 169  3 Final 2021 -04-28  
  
Protocol 6383  [COMPANY_012] Vision Care, Inc. Confidential  10 
PRO SPECIFICATIO  
Page 81 of 169  3 Final 2021 -04-28  
  
Protocol 6383  [COMPANY_012] Vision Care, Inc. Confidential  11 
PRO SPECIFICATIO  
Page 82 of 169  3 Final 2021 -04-28  
  
Protocol 6383  [COMPANY_012] Vision Care, Inc. Confidential  12 
PRO SPECIFICATIO  
Page 83 of 169  3 Final 2021 -04-28  
  
Protocol 6383  [COMPANY_012] Vision Care, Inc. Confidential  13 
PRO SPECIFICATIO  
Page 84 of 169  3 Final 2021 -04-28  
  
Protocol 6383  [COMPANY_012] Vision Care, Inc. Confidential  14 
PRO SPECIFICATIO  
Page 85 of 169  3 Final 2021 -04-28  
  
Protocol 6383  [COMPANY_012] Vision Care, Inc. Confidential  15 
PRO SPECIFICATIO  
Page 86 of 169  3 Final 2021 -04-28  
  
Protocol 6383  [COMPANY_012] Vision Care, Inc. Confidential  16 
PRO SPECIFICATIO  
Page 87 of 169  3 Final 2021 -04-28  
  
Protocol 6383  [COMPANY_012] Vision Care, Inc. Confidential  17 
PRO SPECIFICATIO  
Page 88 of 169  3 Final 2021 -04-28  
  
Protocol 6383  [COMPANY_012] Vision Care, Inc. Confidential  18 
PRO SPECIFICATIO  
Page 89 of 169  3 Final 2021 -04-28  
  
Protocol 6383  [COMPANY_012] Vision Care, Inc. Confidential  19 
PRO SPECIFICATIO  
Page 90 of 169  3 Final 2021 -04-28  
  
Protocol 6383  [COMPANY_012] Vision Care, Inc. Confidential  20 
Page 91 of 169   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PRO  SPECIFICATIO  3 Final  2021 -04-28 
Protocol 6383  [COMPANY_012] Vision Care, Inc. Confidential  21 
PRO SPECIFICATIO  
Page 92 of 169  3 Final 2021 -04-28  
  
Protocol 6383  [COMPANY_012] Vision Care, Inc. Confidential  22 
PRO SPECIFICATIO  
Page 93 of 169  3 Final 2021 -04-28  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CR-6383,  v 4.0 JJVC  CONFIDENTIAL  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 94 of 169   
  
APPENDIX B: PATIENT INSTRUCTION GUIDE  
Will be provided separately.  
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 95 of 169   
  
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT)  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 96 of 169   
  
UltraMFA DW PI[INVESTIGATOR_93796] / US / FITSET 
8184600  
n/a 5573  
BLACK  PMS 
320 
CR-6383, v 4.0  
11 JJVC CONFIDENTIAL  
14 12 13 
Page 97 of 169   
 
2 
  PACKAGE  INSERT  / FITTING  GUIDE   
 
   
 
 
 
 
 SYMBOL REFERENCE GUIDE  
For labels and cartons:  
 
Meets  EU  Packaging  
Directive  
 
Sterilized 
Using Steam  
 
            Caution 
Diameter  
EXP Use-By [CONTACT_93874]  ................................ ................................ .........................  2 
Description  ................................ ................................ ......................  3 
Lens Parameters  Available  ................................ ................................  4 
How the Lens Works  (Actions)  ................................ ...........................  4 
Indications  ................................ ................................ .......................  4 
Contraindications  (Reasons  Not To Use) ................................ ...........  5 
Warnings  ................................ ................................ ..........................  6 
Precautions ................................ ................................ .......................  7 
Adverse  Reactions  ................................ ................................ ........................... 11 
Selection  of Patients  ................................ ................................ ................  13 
Practitioner  Fitting  Sets ................................ ................................ ...........  14 
General  Fitting  Procedure  ................................ ...............................  14 
Pre-Fitting  Examination  ................................ ................................ ... 14 
Lens Power  Selection  ................................ ...............................  14 
Lens Fitting  ................................ ................................ ......................  14 
To Refine  Near Vision  ................................ ...............................  15 
To Refine  Distance  Vision  ................................ ........................  15 
Patient  Education  ................................ ................................ .............  16 
Lens Evaluation  ................................ ................................ ................  16 
Criteria  of a Well-Fitted  Lens ................................ ....................  16 
Characteristics  of a Tight (Steep)  Lens ................................ ..... 17 
Characteristics  of a Loose  (Flat) Lens ................................ ....... 17 CAUTION  
Federal  law restricts  this device  to sale by [CONTACT_35537] a licensed  practitioner.  
IMPORTANT  
This package  insert and fitting  guide has been developed  to provide  practitioners 
with information covering characteristics of the Bausch + Lomb ULTRA 
(samfilcon  A) Multifocal  for Astigmatism  Contact  [CONTACT_93875].  It is effective  as of revision  date on cover and supersedes  all prior 
fitting guides for the product described. Please read carefully and keep this 
information  for future  use. 
This package  insert and fitting  guide is intended  for the eye care practitioner,  but 
should  be made available  to patients  upon request.  The eye care practitioner 
should  provide  the patient  with the patient  instructions  that pertain  to the patient’s 
prescribed  lens and the recommended  wearing  schedule.  
 
 
 
 
 
 
 
 
 
 
 
CAUTION:  Federal  law restricts  this device  to 
sale by [CONTACT_35537] a licensed  practitioner.  
®/TM  are trademarks  of Bausch  & Lomb  Incorporated  or its affiliates.  
© 2019 Bausch & Lomb Incorporated  
Bausch  & Lomb  Incorporated 
[ADDRESS_103906] 
[COMPANY_002]ster,  NY [ZIP_CODE]  [LOCATION_003] 
Printed in the [LOCATION_003]   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rev. 2019-02 
8184600  Prescription 
Only ([LOCATION_003]) 
 
Power  YYYY-MM-DD Effective  Date 
 
Manufacturer  Follow -Up Care ................................ ................................ ........ 18 
Monovision  Fitting  Guidelines  ................................ ................................  19 
Patient  Selection  ................................ ................................ ...... 19 
Eye Selection ................................ ................................ ....... 20 
Special  Fitting  Considerations  ................................ .................  20 
Near Add Determination  ................................ ....................  20 
Trial Lens Fitting  ................................ ................................ ...............  21 
Adaptation  ................................ ................................ .......................  21 
Other  Suggestions  ................................ ................................ .. 22 
Wearing  Schedule  ................................ ................................ ...... 23 
Handling  of Lens ................................ ................................ ............  23 
Patient  Lens Care Directions  ................................ ....................  23 
Frequent/Planned  Replacement  Wear ................................ ......... 23 
Disposable  Wear ................................ ................................ .............  24 
Care for a Sticking  (Nonmoving)  Lens ................................ .............  25 
Emergencies  ................................ ................................ ..............  26 
Reporting  of Adverse  Reactions  ................................ ......................  26 
How Supplied  ................................ ................................ .................  26 
2 
 
DESCRIPTION  
The Bausch  + Lomb ULTRA® (samfilcon  A) Multifocal  for Astigmatism  Contact 
[CONTACT_93876],  samfilcon  A, is a hydrophilic  copolymer  of a siloxane  methacrylate 
and N-vinyl pyrrolidone,  and is 46% water by [CONTACT_93877] a sterile 
borate  buffered  saline with poloxamine  solution.  This lens is tinted  with up to 
200 ppm of Reactive  Dye 246. The Bausch  + Lomb  ULTRA  (samfilcon  A) 
Multifocal for Astigmatism Contact [CONTACT_93878]® Technology 
which  creates  a unique  material  and a hydrophilic  surface.  
The physical/optical properties of the lens are:  
Specific  Gravity:  1.048  
Refractive  Index:  1.411 
Light Transmittance:  C.I.E. value—at least 95% 
Water Content:  46% 
Oxygen Permeabilit y: 114 x 10–11 [cm3O (STP) x cm]/(se c x cm2 x mmHg)  
@ 35°C Polarographic Method (Boundary and 
Edge Corrected)  
The Bausch + Lomb ULTRA (samfilcon A) Multifocal for Astigmatism Contact 
[CONTACT_93879] a 3-Zone Progressive™ Design and an OpticAlign® Design.   
LENS PARAMETERS AVAILABLE  
The Bausch  + Lomb ULTRA  (samfilcon  A) Multifocal  for Astigmatism  Contact  [CONTACT_93880] 
a hemispherical  shell of the following  dimensions:  
Diameter:  14.5mm  
Center  Thickness:  0.05mm  to 0.50mm  
Base Curve:  8.6mm  
Powers:  +4.00D  to -6.00D  in 0.25D  steps 
Add Powers:  Low (+0.75D  to +1.50D)  and 
High (+1.75D  to +2.50D)  
Cylinder  Powers:  -0.75D,  -1.25D  and -1.75D  
Axis: 10° to 180° in 10° increments  
*Additional  powers  may be introduced  over time, check  periodically  for product  availability.  
 
HOW THE LENS WORKS (ACTIONS)  
In its hydrated state, the Bausch + Lomb ULTRA (samfilcon A) Multifocal for 
Astigmatism  Contact  [CONTACT_19550], when placed  on the cornea,  acts as a refracting  medium  to 
focus light rays on the retina.  
INDICATIONS  
Multifocal for Astigmatism Vision Correction  
The Bausch  + Lomb  ULTRA  (samfilcon  A) Multifocal  for Astigmatism  Contact 
[CONTACT_93881]  (myopia, 
hyperopia and astigmatism) and presby[CONTACT_93882]/or not-aphakic persons 
with non-diseased  eyes, exhibiting  astigmatism  of up to 5.00 diopters  and require 
an add power  ranging  from +0.75D  to +5.00D.  
Frequent/Planned Replacement Wear  
When prescribed  for Frequent/Planned  Replacement  Wear, the Bausch  + Lomb 
ULTRA  (samfilcon  A) Multifocal  for Astigmatism  Contact  [CONTACT_93883],  rinsed 
and disinfected  each time it is removed  from the patient’s  eye and discarded  after the 
recommended  wearing  period  prescribed  by [CONTACT_93884].  The lens may 
be disinfected  using  a chemical  disinfection  system.  
Disposable Wear  
When prescribed for Disposable Wear, the Bausch + Lomb ULTRA (samfilcon A) 
Multifocal for Astigmatism Contact [CONTACT_93885].   
CONTRAINDICATIONS 
(REASONS NOT TO USE)  
DO NOT USE the Bausch  + Lomb  ULTRA  (samfilcon  A) Multifocal  for Astigmatism 
Contact  [CONTACT_93886]: 
• Acute and subacute  inflammation  or infection  of the anterior  chamber  of the eye 
• Any eye disease,  injury,  or abnormality  that affects  the cornea,  conjunctiva, 
or eyelids  
• Severe  insufficiency  of lacrimal  secretion  (dry eyes) 
• Corneal  hypoesthesia  (reduced  corneal  sensitivity)  
• Any systemic  disease  that may affect  the eye or be exaggerated  by [CONTACT_93887]  
• Allergic  reactions  of ocular  surfaces  or adnexa  (surrounding  tissue)  that may be 
induced  or exaggerated  by [CONTACT_93888]  
• Allergy  to any ingredient,  such as mercury  or Thimerosal,  in a solution  which is 
to be used to care for the Bausch  + Lomb ULTRA  (samfilcon  A) Multifocal  for 
Astigmatism  Contact  [CONTACT_19550] 
• Any active  corneal  infection  (bacterial,  fungal,  or viral) 
• If eyes become  red or irritated   
WARNINGS  
After a thorough  eye examination,  including  appropriate  medical  background, 
patients  should  be fully apprised  by [CONTACT_93889]. Patients  should  be advised  of the following  warnings 
pertaining  to contact  [CONTACT_13279]: 
• Problems  with contact  [CONTACT_93890]. It is essential  that patients  follow  their eye care practitioner’s 
direction  and all labeling  instructions  for proper  use of lenses  and lens care 
products,  including  the lens case. Eye problems,  including  corneal  ulcers,  can 
develop  rapi[INVESTIGATOR_93797]. 
• Daily wear lenses  are not indicated  for overnight  wear, and patients  should 
be instructed  not to wear lenses  while sleepi[INVESTIGATOR_007] . Clinical  studies  have 
shown  that the risk of adverse  reactions  is increased  when daily wear lenses 
are worn overnight.  
• When prescribed  for Frequent/Planned  Replacement  Wear, the need for 
strict compliance  with the care regimen  including  cleaning  of the lens case, 
wearing restrictions, wearing schedule, and follow-up visit schedule should be 
emphasized  to the patient.  
• Studies  have shown  that contact  [CONTACT_93891] a higher 
incidence  of adverse  reactions  than nonsmokers.  
• If a patient  experiences  eye discomfort,  excessive  tearing,  vision changes,  or 
redness  of the eye, the patient  should  be instructed  to immediately  remove 
the lenses  and promptly  contact  [CONTACT_93892].  
 
 
3 4 5 6 
 
PRECAUTIONS  
Special Precautions for Eye Care Practitioners  
• Due to the small number  of patients  enrolled  in clinical  investigation  of lenses, 
all refractive  powers,  design  configurations,  or lens parameters  available  in the 
lens material  are not evaluated  in significant  numbers.  
Consequently,  when selecting  an appropriate  lens design  and parameters, 
the eye care practitioner  should  consider  all characteristics  of the lens that 
can affect lens performance and ocular health, including oxygen permeability, 
wettability,  central  and peripheral  thickness,  and optic zone diameter.  
• The potential  impact  of these factors  on the patient’s  ocular  health  should 
be carefully  weighed  against  the patient’s  need for refractive  correction; 
therefore,  the prescribing  eye care practitioner  should  carefully  monitor  the 
continuing  ocular  health  of the patient  and lens performance  on eye. 
• Eye care practitioners  should  instruct  the patient  to REMOVE  A LENS 
IMMEDIATELY  if an eye becomes  red or irritated.  
• Fluorescein,  a yellow  dye, should  not be used while the lenses  are on the eyes. 
The lenses  absorb  this dye and become  discolored.  Whenever  fluorescein 
is used in eyes, the eyes should  be flushed  with sterile  saline solution  that is 
recommended  for in-eye use. 
• The patient  should  be instructed  to always  discard  disposable  lenses 
and lenses  worn on a frequent/planned  replacement  schedule  after the 
recommended  wearing  schedule  prescribed  by [CONTACT_93884].  
• As with any contact  [CONTACT_13293], follow -up visits are necessary  to assure  the 
continuing  health  of the patient’s  eyes. The patient  should  be instructed  as to 
a recommended  follow -up schedule.  
• Aphakic  patients  should  not be fitted with Bausch  + Lomb ULTRA 
(samfilcon  A) Multifocal  for Astigmatism  Contact  [CONTACT_93893].  
• Patients  who wear aspheric  contact  [CONTACT_13276],  such as the Bausch  + Lomb 
ULTRA  (samfilcon  A) Multifocal  for Astigmatism  Contact  [CONTACT_19550], to correct 
presby[CONTACT_93894].  Visual  requirements  vary with the individual  and should  be 
considered  when selecting  the most appropriate  type of lens for each patient.  
• Eye care practitioners  should  carefully  instruct  patients  about the following 
lens care and safety  precautions.  It is strongly  recommended  that patients  be 
provided  with a copy of the Bausch  + Lomb ULTRA  (samfilcon  A) Multifocal 
for Astigmatism Contact [CONTACT_93895]  + Lomb and understand  its contents  prior to dispensing  the lenses.  Handling Precautions  
• Always wash and rinse hands before handling lenses. Do not get cosmetics, 
lotions,  soaps,  creams,  deodorants,  or sprays  in the eyes or on the lenses.  It is best 
to put on lenses  before  putting  on makeup.  Water-based cosmetics  are less likely 
to damage  lenses  than oil-based  products.  
• Be sure that before  leaving  the eye care practitioner’s  office,  the patient  is able to 
remove  lenses  promptly  or have someone  else available  to remove  them. 
• Be certain  that the fingers  or hands  are free of foreign  materials  before  touching 
lenses,  as microscopic  scratches  of the lenses  may occur, causing  distorted  vision 
and/or  injury  to the eye. 
• Always  handle  lenses  carefully  and avoid droppi[INVESTIGATOR_93798]. 
• Do not touch  the lens with fingernails.  
• Carefully follow the handling, insertion, removal, cleaning, disinfecting, storing and 
wearing  instructions  in the Patient  Information  Booklet  for the Bausch  + Lomb 
ULTRA (samfilcon A) Multifocal for Astigmatism Contact [CONTACT_93896].  
• Never use tweezers  or other tools to remove  lenses  from the lens container  unless 
specifically  indicated  for that use. Pour the lens into the hand. 
Lens Wearing Precautions  
• Never wear lenses  beyond  the period  recommended  by [CONTACT_93884].  
• If the lens sticks (stops  moving)  on the eye, follow  the recommended  directions  on 
Care for a Sticking  (Nonmoving)  Lens. The lens should  move freely on the eye for 
the continued  health  of the eye. If nonmovement  of the lens continues,  the patient 
should  be instructed  to immediately  consult  his or her eye care practitioner.  
• Avoid,  if possible,  all harmful  or irritating  vapors  and fumes  while wearing  lenses.  
• If aerosol  products  are used while wearing  lenses,  exercise  caution  and keep eyes 
closed  until the spray has settled.  Solution Precautions  
Eye injury  due to irritation  or infection  may result from lens contamination.  To reduce 
the risk of contamination,  review  the appropriate  manufacturer’s  labeled  lens care 
instructions  with the patient.  
• Always  use fresh, unexpi[INVESTIGATOR_93799].  
• Always  follow  directions  in the package  inserts  for the use of contact 
[CONTACT_93897].  
• Sterile unpreserved solutions, when used, should be discarded after the time 
specified  in the labeling  directions.  
• You should  fill your lens case with fresh solution  every time you store your 
lenses  and never “top-off” or re-use solution.  You should  discard  your solution 
immediately  after your lenses  have been removed  from the lens case. 
• Always  keep the lenses  completely  immersed  in the recommended  storage 
solution  when lenses  are not being worn (stored).  Prolonged  periods  of drying 
will damage  lenses.  Follow  the lens care directions  for Care for a Dried Out 
(Dehydrated)  Lens in the Patient  Information  Booklet  if lens surface  does become 
dried out. 
• Do not use saliva or anything  other than the recommended  solution  for lubricating 
or wetting  lenses.  
• Tap water,  distilled  water or homemade  saline should  not be used as a substitute 
for any component  in the lens care regimen  since they have been associated  with 
an Acanthamoeba  keratitis  infection.  
• Never use conventional  hard contact  [CONTACT_93898].  
• Do not mix or alternate  lens care systems  or solutions  unless  indicated  in the lens 
care system  labeling.  
• Do not heat the chemical  disinfection  solution  or lenses.  Lens Case Precautions  
• Contact  [CONTACT_93899] a source  of bacterial  growth.  To prevent 
contamination  and to help avoid serious  eye injury,  always  empty  and rinse 
the lens case with fresh,  sterile  rinsing  solution  and allow to air-dry. 
• Lens cases should  be replaced  at least every three months  or as 
recommended  by [CONTACT_93900].  
Topi[INVESTIGATOR_93800]  
• As with any contact  [CONTACT_13293], follow -up visits are necessary  to assure  the 
continuing  health  of the eyes. The patient  should  be instructed  as to a 
recommended  follow -up schedule.  
• Patients  should  be advised  about wearing  lenses  during  sporting  and water 
related  activities.  Exposure  to water while wearing  contact  [CONTACT_93901],  water skiing  and hot tubs may increase  the risk of ocular 
infection  including,  but not limited  to, Acanthamoeba  keratitis.  
• Certain medications, such as antihistamines, decongestants, diuretics, muscle 
relaxants,  tranquilizers,  and those for motion  sickness  may cause dryness  of 
the eye, increased  lens awareness,  or blurred  vision.  Should  such conditions 
exist, proper remedial measures should be prescribed. Depending on the 
severity,  this could include  the use of lubricating  drops that are indicated  for 
use with soft contact  [CONTACT_93902]. 
• Oral contraceptive  users could develop  visual changes  or changes 
in lens tolerance when using contact [CONTACT_13276]. Patients should be 
cautioned  accordingly.  
Who Should Know That the Patient is Wearing Contact [CONTACT_32993]  
• Patients  should  inform  their doctor  (health  care professional)  about being a 
contact  [CONTACT_35560].  
• Patients  should  always  inform  their employer  of being a contact  [CONTACT_35560]. 
Some jobs may require  the use of eye protection  equipment  or may require 
that you do not wear lenses.  
 
 
 
7 8 9 10 
 
ADVERSE REACTIONS  
The patient should be informed that the following problems may occur:  
• Eyes stinging,  burning,  itching  (irritation),  or other eye pain 
• Comfort  is less than when lens was first placed  on eye 
• Abnormal  feeling  of something  in the eye (foreign  body, scratched  area) 
• Excessive  watering  (tearing)  of the eyes 
• Unusual  eye secretions  
• Redness  of the eyes 
• Reduced  sharpness  of vision (poor visual acuity)  
• Blurred vision, rainbows, or halos around objects  
• Sensitivity  to light (photophobia)  
• Dry eyes 
If the patient  notices  any of the above,  he or she should  be instructed  to: 
• Immediately  remove  the lenses.  
• If the discomfort  or problem  stops,  the patient  should  look closely  at the lens. 
If the lens is in any way damaged,  do not put the lens back on the eye. Place 
the lens in the storage  case and contact  [CONTACT_93884].  If the lens 
has dirt, an eyelash,  or other foreign  body on it, or the problem  stops and 
the lens appears  undamaged,  the patient  should  thoroughly  clean,  rinse, 
and disinfect  the lenses;  then reinsert  them. After reinsertion,  if the problem  
continues,  the patient  should  immediately  remove  the lenses  and consult 
his or her eye care practitioner.  
If the above symptoms  continue  after removal  of the lens, or upon reinsertion 
of a lens, or upon insertion  of a new lens, the patient  should  immediately 
remove the lenses and contact [CONTACT_93903], who must determine the need for examination, treatment or 
referral without delay. (See Important Treatment Information for Adverse 
Reactions.) A serious conditi on such as infection, corneal ulcer, corneal 
vascularization,  or iritis may be present,  and may progress  rapi[INVESTIGATOR_375].  
Less serious  reactions  such as abrasions,  epi[INVESTIGATOR_93801].  Important Treatment Information for Adverse Reactions  
Sight-threatening  ocular  complications  associated  with contact  [CONTACT_93904][INVESTIGATOR_375],  and therefore  early recognition  and treatment  of problems  are critical.  
Infectious  corneal  ulceration  is one of the most serious  potential  complications, 
and may be ambiguous  in its early stage. Signs and symptoms  of infectious  corneal 
ulceration include discomfort, pain, inflammation, purulent discharge, sensitivity to 
light, cells and flare, and corneal  infiltrates.  
Initial symptoms  of a minor  abrasion  and an early infected  ulcer are sometimes 
similar.  Accordingly,  such epi[INVESTIGATOR_93802],  if not treated  properly,  may develop  into an 
infected  ulcer. In order to prevent  serious  progression  of these conditions,  a patient 
presenting  symptoms  of abrasions  or early ulcers  should  be evaluated  as a potential 
medical  emergency,  treated  accordingly,  and be referred  to a corneal  specialist  when 
appropriate.  Standard  therapy  for corneal  abrasions  such as eye patching  or the use 
of steroids  or steroid/antibiotic  combination  may exacerbate  the condition.  If the 
patient  is wearing  a contact  [CONTACT_93905],  the lens should 
be removed  immediately  and the lens and lens care products  retained  for analysis 
and culturing.  SELECTION OF PATIENTS  
The eye care practitioner  should  not fit patients  who cannot  or will not adhere  to a 
recommended  care or replacement  regimen,  or are unable  to place and remove 
the lenses  should  not be provided  with them.  Failure  to follow  handling  and cleaning 
instructions  could lead to serious  eye infections  which  might  result in corneal  ulcers.  
Patient  communication  is vital because  it relates  not only to patient  selection  but also 
to ensure  compliance.  It is also necessary  to discuss  the information  contained  in the 
Patient  Information  Booklet  with the patient  at the time of the initial examination.  
Patients  selected  to wear Bausch  + Lomb  ULTRA  (samfilcon  A) Multifocal  for 
Astigmatism  Contact  [CONTACT_93906],  general  health  and cooperation.  The eye care practitioner  must take care 
in selecting, examining and instructing contact [CONTACT_93907]. Patient hygiene and 
willingness to follow practitioner instructions are essential to their success.  
A detailed  history  is crucial  to determining  patient  needs  and expectations.  Your 
patient  should  be questioned  regarding  vocation,  desired  lens wearing  time (full or 
part time),  and desired  lens usage  (reading,  recreation  or hobbies).  
Initial evaluation  of the trial lens should  be preceded  by a complete  eye examination, 
including  visual  acuity  with and without  correction  at both distance  and near, 
keratometry  and slit lamp examination.  
It is normal  for the patient  to experience  mild symptoms  such as lens awareness, 
variable  vision,  occasional  tearing  (watery  eyes) and slight redness  during  the 
adaptation  period.  Although  the adaptation  period  varies for each individual,  generally 
within  one week these symptoms  will disappear.  
If these symptoms persist, the patient should be instructed to contact [CONTACT_93908].  PRACTITIONER FITTING SETS  
Lenses  must be discarded  after a single  use and must not be used from patient 
to patient.  
GENERAL FITTING PROCEDURE  
1. Pre-Fitting  Examination  
A pre -fitting patient history and examination are necessary to:  
• Determine  whether  a patient  is a suitable  candidate  for contact  [CONTACT_13276] 
(consider  patient  hygiene  and mental  and physical  state),  
• Make ocular  measurements  for initial contact  [CONTACT_93909],  and 
• Collect  and record  baseline  clinical  information  to which  post-fitting 
examination  results  can be compared.  
A pre-fitting  examination  should  include  spherocylinder  refraction  and VA, 
keratometry,  and biomicroscopic  examination.  
2. Lens Power Selection  
a. Update  spectacle  refraction  and Add power.  
b. Determine  ocular  dominance.  
c. Select  toric lens power,  adjusting  for vertex  distance  if necessary.  
d. Select  Add power  for both eyes, following  the guidance  below.  
• Bausch  + Lomb ULTRA  (samfilcon  A) Multifocal  for Astigmatism 
Contact  [CONTACT_93910]: +0.75D  to +1.50D  
• Bausch  + Lomb ULTRA  (samfilcon  A) Multifocal  for Astigmatism 
Contact  [CONTACT_93911]: +1.75D  to +2.50D  
3. Lens Fitting  
a. Allow lens to equilib rate for at least 10 minutes before assessing fit and vision. 
b. Confirm  axis orientation.  
c. Evaluate  distance  and near vision binocularly  in normal  room illumination.  
d. If vision at distance  and near are satisfactory,  dispense  lenses  and schedule 
follow -up exam within  1-2 weeks.  

CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 98 of 169   
 4. To Refine  Near Vision  
If patient is wearing two Low Add lenses:  
• Refinement  1: 
Place Bausch + Lomb ULTRA (samfilcon A) Multifocal for Astigmatism 
Contact [CONTACT_93912]-dominant eye while keepi[INVESTIGATOR_93803] + Lomb ULTRA (samfilcon A) Multifocal for Astigmatism 
Contact [CONTACT_93913]. 
• Refinement  2: 
If vision is still unsatisfactory,  continue  adding  +0.25D  at a time to the 
non-dominant  eye using handheld  lenses.  Adjust  contact  [CONTACT_93914].  
If patient is wearing two High Add lenses:  
• Refinement  1: 
Add +0.25D to the non -dominant eye.  
• Refinement  2: 
If vision is still unsatisfactory,  continue  adding  +0.25D  at a time to the 
non-dominant  eye using handheld  lenses.  
5. To Refine  Distance  Vision  
If patient is wearing two Low Add lenses:  
• Refinement  1: 
Fit Bausch  + Lomb ULTRA  for Astigmatism  in dominant  eye while 
keepi[INVESTIGATOR_93804]  + Lomb  ULTRA  (samfilcon  A) Multifocal  for 
Astigmatism  Contact  [CONTACT_93915]-dominant  eye. 
• Refinement  2: 
If vision  is still unsatisfactory,  add -0.25D  at a time to dominant  eye using 
hand held lenses.  Adjust  contact  [CONTACT_93916].  
If patient is wearing two High Add lenses:  
• Refinement  1: 
Fit with Bausch  + Lomb ULTRA  (samfilcon  A) Multifocal  for Astigmatism 
Contact  [CONTACT_93917][INVESTIGATOR_93804]  + Lomb 
ULTRA  (samfilcon  A) Multifocal  for Astigmatism  Contact  [CONTACT_93918]-dominant  eye. 
• Refinement  2: 
If vision  is still unsatisfactory,  add -0.25D  at a time to dominant  eye using 
hand held lenses.  Adjust  contact  [CONTACT_93916].  6. Patient  Education  
All patients  do not function  equally  well with multifocal  correction.  Patients  may not 
perform  as well for certain  tasks with this correction  as they have with multifocal 
reading  glasses.  Each patient  should  understand  that multifocal  correction  can create 
a vision compromise  that may reduce  visual acuity  and depth perception  for distance 
and near tasks.  During  the fitting  process  it is necessary  for the patient  to realize  the 
disadvantages  as well as the advantages  of clear near vision in straight  ahead  and 
upward  gaze that multifocal  contact  [CONTACT_93919].  
7. Lens Evaluation  
a. To determine  proper  lens parameters,  observe  the lens relationship  to the eye 
using a slit lamp. 
• Movement:  The lens should  provide  discernible  movement  with: 
— Primary  gaze blink 
— Upgaze  blink 
— Upgaze  lag 
• Centration:  The lens should  provide  full corneal  coverage  
b. Lens evaluation allows the contact [CONTACT_93920]/cornea 
relationship  in the same manner  as would  be done with any soft lens. If after the 
lens has settled  on the eye, the patient  reports  lens sensation,  or if the lens is 
moving or decentering excessively, the lens should not be dispensed. Alternatively, 
if the patient  reports  variable  vision,  or if the lens shows  insufficient  movement,  the 
lens should  not be dispensed.  
8. Criteria  of a Well-Fitted  Lens 
If the lens fully covers  the cornea,  provides  discernible  movement  after a blink, is 
comfortable  for the patient  and provides  satisfactory  visual performance,  it is a 
well-fitted lens and can be dispensed.  9. Characteristics  of a Tight (Steep)  Lens 
A lens which  is much too steep may subjectively  and objectively  cause distortion  which 
will vary after a blink. However,  if a lens is only marginally  steep,  the initial subjective 
and objective  vision  and comfort  findings  may be quite good. A marginally  steep lens 
may be differentiated  from a properly  fitted lens by [CONTACT_93921].  
A properly  fitted lens will tend to slide downward  approximately  0.5mm  while a steep 
lens will remain  relatively  stable in relationship  to the cornea,  particularly  with the blink. 
Toric Lens: With your finger,  gently  rotate  the lens approximately  45° to the temporal 
side. It should reorien t with 5 to 10 blinks back to the same stabilized position.  
10. Characteristics  of a Loose  (Flat) Lens 
A lens that is too flat will decenter,  especially  on post-blink, have a tendency  to edge 
lift inferiorly  and sit on the lower lid, rather  than positioning  between  the sclera and 
palpebral  conjunctiva.  A flat fitted lens will have a tendency  to be uncomfortable  and 
irritating  with fluctuating  vision.  A flat fitted lens has a tendency  to drop or lag greater 
than 2.0mm  on upgaze  post-blink. 11. Follow -Up Care 
a. Follow -up examinations  are necessary  to ensure  continued  successful  contact 
[CONTACT_13279]. From the day of dispensing,  the following  schedule  is a suggested 
guideline  for follow -up. 
• 24 hours 
• 1 to 2 weeks 
• Every six months  thereafter  
At the initial follow -up evaluations the eye care practitioner should again 
reassure the patient that any of the previously described adaptive symptoms 
are normal, and that the adaptation period should be relatively brief. 
Depending  on the patient’s  prior experience  with contact  [CONTACT_93922]/or 
continuous  wear, the eye care practitioner  may consider  prescribing  a one 
week period  of daily wear adaptation  prior to beginning  continuous  wear. 
b. Prior to a follow -up examination,  the contact  [CONTACT_93923] [ADDRESS_103907] on the eyes, evaluate  fitting  performance  to assure  that 
Criteria  of a Well-Fitted Lens continue  to be satisfied.  Examine  the lenses 
closely  for surface  deposition  and/or  damage.  
d. After the lens removal, instill sodium fluorescein [unless contraindicated] into 
the eyes and conduct  a thorough  biomicroscopy  examination.  
1. The presence  of vertical  corneal  striae in the posterior  central  cornea 
and/or corneal neovascularization may be indicative of excessive 
corneal  edema.  
2. The presence  of corneal  staining  and/or  limbal -conjunctival  hyperemia 
can be indicative  of an unclean  lens, a reaction  to solution  preservatives, 
excessive  lens wear, and/or  a poorly  fitting  lens. 
3. Papi[INVESTIGATOR_93805]/or 
damaged  lens. 
If any of the above  observations  are judged  abnormal,  various  professional 
judgments  are necessary  to alleviate  the problem  and restore  the eye to 
optimal  conditions.  If the Criteria  of a Well-Fitted Lens are not satisfied 
during  any follow -up examination,  the patient  should  be re-fitted with a more 
appropriate  lens. 
 
 
[ADDRESS_103908] adequately  corrected 
distance  and near visual acuity  in each eye. The amblyopic  patient  or the 
patient  with significant  astigmatism  (greater  than one [1] diopter)  in one 
eye may not be a good candidate  for monovision  with the Bausch  + Lomb 
ULTRA  (samfilcon  A) Multifocal  for Astigmatism  Contact  [CONTACT_32993].  
Occupational  and environmental  visual demands  should  be considered. 
If the patient  requires  critical  vision (visual  acuity and stereopsis)  it should 
be determined  by [CONTACT_93924].  
Monovision  contact  [CONTACT_93925]: 
1. Visually demanding situations such as operating potentially dangerous 
machinery  or performing  other potentially  hazardous  activities;  and 
2. Driving  automobiles  (e.g., driving  at night).  Patients  who cannot  pass their 
state driver’s  license  requirements  with monovision  correction  should  be 
advised  to not drive with this correction,  OR may require  that additional 
over-correction  be prescribed.  
b. Patient  Education  
All patients do not function equally well with monovision correction. 
Patients  may not perform  as well for certain  tasks with this correction  as 
they have with bifocal  reading  glasses.  Each patient  should  understand 
that monovision  can create  a vision  compromise  that may reduce visual 
acuity and depth perception  for distance  and near tasks. During  the fitting 
process  it is necessary  for the patient  to realize  the disadvantages  as well as 
the advantages  of clear near vision  in straight  ahead  and upward  gaze that 
monovision  contact  [CONTACT_93919].  2. Eye Selection  
Generally,  the non-dominant  eye is corrected  for near vision.  The following  test for eye 
dominance  can be used. 
a. Ocular  Preference  Determination  Methods  
• Method 1 —Determine which eye is the “sighting dominant eye”. Have the 
patient  point to an object  at the far end of the room.  Cover  one eye. If the 
patient  is still pointing  directly  at the object,  the eye being used is the dominant 
(sighting)  eye. 
• Method  2—Determine  which  eye will accept  the added  power  with the least 
reduction  in vision.  Place a trial spectacle  near add lens in front of one eye 
and then the other while the distance  refractive  error correction  is in place for 
both eyes. Determine  whether  the patient  functions  best with the near add 
lens over the right or left eye. 
b. Refractive  Error Method  
For anisometropic  corrections,  it is generally  best to fit the more hyperopic  (less 
myopic)  eye for distance  and the more myopic  (less hyperopic)  eye for near. 
c. Visual  Demands  Method  
Consider  the patient’s  occupation  during  the eye selection  process  to determine 
the critical  vision requirements.  If a patient’s  gaze for near tasks is usually  in one 
direction  correct  the eye on that side for near. 
Example:  
A secretary  who places  copy to the left side of the desk will usually  function  best 
with the near lens on the left eye. 
3. Special  Fitting  Considerations  
Unilateral Lens  Correction  
There are circumstances  where  only one contact  [CONTACT_35571].  As an example, 
an emmetropic  patient  would  only require  a near lens while a bilateral  myope  may 
require  only a distance  lens. 
Example:  
A presby[CONTACT_93926]  a +1.[ADDRESS_103909] a 
+1.75 diopter lens on the near eye and the other eye left without a lens. 
A presby[CONTACT_93927]  a +1.50  diopter  add who is –2.50 diopters  myopic 
in the right eye and –1.[ADDRESS_103910] the right eye 
corrected  for distance  and the left uncorrected  for near. 
4. Near Add Determination  
Always  prescribe  the lens power  for the near eye that provides  optimal  near acuity  at 
the midpoint  of the patient’s  habitual  reading  distance.  However,  when more than one 
power  provides  optimal  reading  performance,  prescribe  the least plus (most minus) 
of the powers.  5. Trial Lens Fitting  
A trial fitting  is performed  in the office  to allow the patient  to experience  monovision 
correction.  Lenses  are fit according  to the directions  in the general  fitting guidelines.  
Case history  and standard  clinical  evaluation  procedure  should  be used to determine 
the prognosis.  Determine  which  eye is to be corrected  for distance  and which  eye is 
to be corrected  for near. Next determine  the near add. With trial lenses  of the proper 
power  in place observe  the reaction  to this mode  of correction.  
Immediately  after the correct  power  lenses  are in place,  walk across  the room and 
have the patient  look at you. Assess  the patient’s  reaction  to distance  vision under 
these circumstances.  Then have the patient  look at familiar  near objects  such as a 
watch  face or fingernails.  Again assess  the reaction.  As the patient  continues  to look 
around  the room at both near and distant  objects,  observe  the reactions.  Only after 
these vision tasks are completed  should  the patient  be asked  to read print. Evaluate 
the patient’s  reaction  to large print (e.g., typewritten  copy) at first and then graduate  to 
newsprint  and finally  smaller  type sizes. 
After the patient’s performance under the above conditions is completed, tests of 
visual acuity and reading ability under conditions of moderately dim illumination should 
be attempted.  
An initial unfavorable  response  in the office,  while indicative  of a guarded  prognosis, 
should  not immediately  rule out a more extensive  trial under  the usual conditions  in 
which  a patient  functions.  
6. Adaptation  
Visually demanding situations should be avoided during the initial wearing period.  
A patient  may at first experience  some mild blurred  vision,  dizziness,  headaches,  and 
a feeling  of slight imbalance.  You should  explain  the adaptational  symptoms  to the 
patient.  These  symptoms  may last for a brief minute  or for several  weeks.  The longer 
these symptoms  persist,  the poorer  the prognosis  for successful  adaptation.  
To help in the adaptation  process  the patient  can be advised  to first use the lenses  in a 
comfortable  familiar  environment  such as in the home.  
Some patients  feel that automobile  driving  performance  may not be optimal  during 
the adaptation  process.  This is particularly  true when driving  at night.  Before  driving  a 
motor  vehicle,  it may be recommended  that the patient  be a passenger  first to make 
sure that their vision is satisfactory  for operating  an automobile.  During  the first several 
weeks  of wear (when  adaptation  is occurring),  it may be advisable  for the patient  to 
only drive during  optimal  driving  conditions.  After adaptation  and success  with these 
activities,  the patient  should  be able to drive under  conditions  with caution.  7. Other  Suggestions  
The success  of the monovision  technique  may be further  improved  by [CONTACT_93928].  
• Having  a third contact  [CONTACT_13293] (distance  power)  to use when critical  distance 
viewing  is needed.  
• Having  a third contact  [CONTACT_13293] (near power)  to use when critical  near viewing 
is needed.  
• Having  supplemental  spectacles  to wear over the monovision  contact  [CONTACT_93929]. 
This is particularly applicable for those patients who cannot meet state 
licensing  requirements  with a monovision  correction.  
• Make use of proper  illumination  when carrying  out visual  tasks. 
Success  in fitting monovision  can be improved  by [CONTACT_93930]:  
• Reverse  the distance  and near eyes if a patient  is having  trouble  adapting.  
• Refine  the lens powers  if there is trouble  with adaptation.  Accurate  lens power 
is critical  for presby[CONTACT_93931].  
• Emphasize  the benefits  of the clear near vision in straight  ahead  and upward 
gaze with monovision.  
• The decision  to fit a patient  with a monovision  correction  is most 
appropriately  left to the eye care practitioner  in conjunction  with the 
patient  after carefully  considering  the patient’s  needs.  
• All patients should be supplied with a copy of the Bausch + Lomb 
ULTRA  (samfilcon  A) Multifocal  for Astigmatism  Contact  [CONTACT_93932].  
 
19 20 21 22 
 
WEARING SCHEDULE  
The wearing  and replacement  schedules  should  be determined  by [CONTACT_93933].  Regular  checkups,  as determined  by [CONTACT_93884],  are 
extremely  important.  
Daily Wear  
There may be a tendency  for the daily wear patient  to over wear the lenses  initially. 
Therefore,  the importance  of adhering  to a proper,  initial daily wearing  schedule 
should  be stressed  to these patients.  The wearing  schedule  should  be determined 
by [CONTACT_93884].  The wearing  schedule  chosen  by [CONTACT_93934].  
Disposable Lens Wear  
No lens care is needed.  The lenses  are discarded  every time they are removed 
from the eye. Lenses  should  only be cleaned,  rinsed  and disinfected  on an 
emergency  basis when replacement  lenses  are not available.  
Frequent/Planned Replacement Wear  
When removed  between  replacement  periods,  lenses  must be cleaned  and 
disinfected  before  reinsertion,  or be discarded  and replaced  with a new lens. 
HANDLING OF LENS  
Patient Lens Care Directions  
When lenses  are dispensed,  the patient  should  be provided  with appropriate 
and adequate  instructions  and warnings  for lens care handling.  The eye care 
practitioner  should  recommend  appropriate  and adequate  procedures  and 
products  for each individual  patient  in accordance  with the particular  lens wearing 
schedule  and care system  selected  by [CONTACT_93935],  the specific  instructions  for 
such products  and the particular  characteristics  of the patient.  
Frequent/Planned Replacement Wear  
For complete  information  concerning  the care, cleaning  and disinfection  of 
contact  [CONTACT_93936]  + Lomb ULTRA  (samfilcon  A) Multifocal  for 
Astigmatism  Contact  [CONTACT_93937].  Disposable Wear  
For complete information concerning emergency lens care, refer to the 
Bausch + Lomb ULTRA (samfilcon A) Multifocal for Astigmatism Contact [CONTACT_93938].  
a. Soaking  and Storing  Lenses  
Instructions for Use:  
Use only fresh contact  [CONTACT_93939] (store)  your lenses.  
WARNING:  
Do not reuse or “top-off” old solution  left in lens case since solution  reuse reduces 
effective  lens disinfection  and could lead to severe  infection,  vision loss or blindness. 
“Toppi[INVESTIGATOR_007] -off” is the addition  of fresh solution  to solution  that has been sitting  in 
the case.  
b. Rub and Rinse  Time 
Instructions for Use:  
Follow  the complete  recommended  lens rubbing  and rinsing  times in the labeling  of 
the solution  used for cleaning,  disinfecting  and soaking  lenses  to adequately  disinfect 
lenses  and reduce  the risk of contact  [CONTACT_93940].  
WARNING:  
• Rub and rinse lenses  for the recommended  amount  of time to help prevent 
serious  eye infections.  
• Never  use water, saline solution,  or rewetting  drops to disinfect  lenses.  These 
solutions  will not disinfect  lenses;  not using the recommended  disinfectant  can 
lead to serious  infection,  vision  loss or blindness.  
c. Lens Case Care 
Instructions for Use:  
• Clean contact [CONTACT_93941], sterile disinfecting 
solution/contact  [CONTACT_93942].  Never  use water.  Cleaning  should  be followed  by 
[CONTACT_93943], sterile  disinfecting  solutions  (never  use water)  and wipi[INVESTIGATOR_93806], clean tissue  is recommended.  Never air-dry or recap the 
lens case lids after use without  any additional  cleaning  methods.  If air-drying,  be 
sure that no residual  solution  remains  in the case before  allowing  it to air-dry. 
• Replace  lens case at least every three months,  or as directed  by [CONTACT_93944].  
• Contact  [CONTACT_93899] a source  of bacterial  growth.  
WARNING:  
Do not store lenses  or rinse lens case with water or any non-sterile  solution.  Only 
use fresh solution  so you do not contaminate  lenses  or lens case. Use of non-sterile 
solution  can lead to severe  infection,  vision  loss or blindness.  d. Water  Activity  
Instructions for Use:  
Do not expose contact [CONTACT_35551].  
WARNING:  
Water can harbor  microorganisms  that can lead to severe  infection,  vision  loss or 
blindness.  If your lenses  have been submersed  in water when swimming  in pools, 
lakes, or oceans,  discard  them and replace  them with a new pair. Ask your eye 
care practitioner  for recommendations  about wearing  lenses  during  any activity 
involving  water. 
e. Discard  Date on Solution  Bottle  
Instructions for Use:  
Discard  any remaining  solution  after the recommended  time period  indicated  on the 
bottle  of the solution  used for disinfecting  and soaking  contact  [CONTACT_13276].  
WARNING:  
Using solution beyond the discard date could result in contamination of the solution 
and can lead to severe infection, vision loss or blindness.  
CARE  FOR  A STICKING  (NONMOVING)  LENS  
If the lens sticks (stops  moving),  the patient  should  be instructed  to use a lubricating  or 
rewetting  solution  in their eye. The patient  should  be instructed  to not use plain water, 
or anything  other than the recommended  solutions.  The patient  should  be instructed 
to contact  [CONTACT_93945],  and to not attempt  to remove  the lens except 
on the advice  of the eye care practitioner.  EMERGENCIES  
If chemicals of any kind (household products, gardening solutions, laboratory 
chemicals, etc.) are splashed into your eyes, you should: FLUSH EYES 
IMMEDIATELY WITH TAP WATER AND THEN REMOVE LENSES 
PROMPTLY.  CONTACT  [CONTACT_93946] 
A HOSPI[INVESTIGATOR_93807].  
REPORTING OF ADVERSE REACTIONS  
All serious  adverse  experiences  and adverse  reactions  observed  in patients 
wearing  Bausch  + Lomb ULTRA  (samfilcon  A) Multifocal  for Astigmatism 
Contact  [CONTACT_93947]: 
Bausch & Lomb Incorporated 
[ADDRESS_103911] 
[COMPANY_002]ster, [LOCATION_001] [ZIP_CODE] [LOCATION_003] 
Toll Free Telephone Number  
In the Continental U.S., Alaska, Hawaii 
[PHONE_2190] 
In Canada  
[PHONE_2191] (Option 1 – English, Option 2 – French)  
HOW SUPPLIED  
Each sterile  lens is supplied  in a plastic  blister  package  containing  borate  buffered 
saline with poloxamine solution. The container is marked with the manufacturing 
lot number  of the lens, the base curve,  sphere,  diameter  and expi[INVESTIGATOR_78288]. 
 
23 24 25 26 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 99 of 169   
  
APPENDIX D: PRESBY[CONTACT_93948] & Johnson Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 100 of 169   
  
APPENDIX E: OCULAR DOMINANCE  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 101 of 169   
  
APPENDIX F: BINOCULAR OVER REFRACTION  
 
 
 
 
 
 
 
 
 
 
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 102 of 169   
  
APPENDIX G:  
• DETERMINATION OF NEAR  ADDITION  
• NEAR logMAR VISUAL ACUITY MEASUREMENT  PROCEDURE  
• LENS FITTING  CHARACTERISTICS  
• SUBJECT REPORTED OCULAR SYMPTOMS  
•  DETERMINATION OF DISTANCE  SPHEROCYLINDRICAL 
REFRACTIONS  
• BIOMICROSCOPY  SCALE  
• KERATOMETRY  
• DISTANCE AND NEAR VISUAL ACUITY EVALUATION  
• TORIC FIT  EVALUATION  
• ETDRS DISTANCE VISUAL ACUITY MEASURMENT PROCEDURE  
•  VISUAL ACUITY CHART LUMINANCE AND ROOM  ILLUMINATION 
TESTING   
 
 
 
 
 
 
 
 
 
 
 
 
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 103 of 169   
  
DETERMINATION OF NEAR ADDITION  
Title:  
Document Type: 
Document Number:  Determination of Near Addition  
Revision Number:  5 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 104 of 169   
  
  
 
 
 
 
 
 
 
Title:  
Document Type: 
Document Number:  Determination of Near Addition  
Revision Number:  5 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 105 of 169   
  
 
Title:  
Document Type: 
Document Number:  Determination of Near Addition  
Revision Number:  5 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 106 of 169   
  
 
 
 
 
 
Title:  
Document Type: 
Document Number:  Determination of Near Addition  
Revision Number:  5 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 107 of 169   
  
 
 
 
Title:  
Document Type: 
Document Number:  Determination of Near Addition  
Revision Number:  5 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 108 of 169   
  
  
 
 
 
 
 
 
 
 
 
 
 
Clinica l Study Protocol  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 109 of 169   
 [COMPANY_012] Vision Care, Inc.  
 
NEAR LOGMAR VISUAL ACUITY MEASUREMENT PROCEDURE  
Title:  Near LogMAR Visual Acuity Measurement Procedure  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 110 of 169   
 Document Type:      
Document Number:   Revision Number: 9  
 
 
 
 
 
 
 
 
 
 
 
Title:  Near LogMAR Visual Acuity Measurement Procedure  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 111 of 169   
 Document Type:      
Document Number:   Revision Number: 9  
 
 
 
 
 
 
 
 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 112 of 169   
 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
LENS FITTING CHARACTERISTICS  
Title:  
Document Type: 
Document Number:  Lens Fitting Characteristics  
Revision Number:  6 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 113 of 169   
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Title:  
Document Type: 
Document Number:  Lens Fitting Characteristics  
Revision Number:  6 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 114 of 169   
  
  
 
 
 
 
 
 
 
 
Title:  
Document Type: 
Document Number:  Lens Fitting Characteristics  
Revision Number:  6 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 115 of 169   
  
 
 
 
 
 
Title:  
Document Type: 
Document Number:  Lens Fitting Characteristics  
Revision Number:  6 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 116 of 169   
  
 
  
Title:  
Document Type: 
Document Number:  Lens Fitting Characteristics  
Revision Number:  6 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 117 of 169   
  
 
Clinical Study Protocol  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 118 of 169   
 [COMPANY_012] Vision Care, Inc.  
 
SUBJECT REPORTED OCULA R SYMPTOMS  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 119 of 169   
 Title:  Subject Reported Ocular Symptoms/Problems  
Document Type:      
Document Number:   Revision Number:  4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 120 of 169   
 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
DETERMINATION  OF DISTANCE  SPHEROCYLINDRICAL 
REFRACTIONS  
Title:  Determination of Distance Spherocylindrical Refractive Error  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 121 of 169   
 Document Type:      
Document Number:   Revision Number:  5 
 
 
 
 
 
 
 
 
 
 
 
 
Title:  Determination of Distance Spherocylindrical Refractive Error  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 122 of 169   
 Document Type: 
Document Number:   
Revision Number:  5 
Title:  Determination of Distance Spherocylindrical Refractive Error  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 123 of 169   
 Document Type:      
Document Number:   Revision Number:  5 
 
 
 
 
 
Title:  Determination of Distance Spherocylindrical Refractive Error  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 124 of 169   
 Document Type:      
Document Number:   Revision Number:  5 
 
 
 
 
 
Title:  Determination of Distance Spherocylindrical Refractive Error  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 125 of 169   
  
 
 
 
 
 
 
 
 
 
 Document Type:  
Document Number:  Revision Number: 5  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 126 of 169   
 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
BIOMICROSCOPY SCALE  
Title:  Biomicroscopy Scale  
Page 1 of 5 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 127 of 169   
 Document Type:      
Document Number:   Revision Number: 10  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Title:  Biomicroscopy Scale  
Page 2 of 5 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 128 of 169   
 Document Type:      
Document Number:   Revision Number: 10  
 
Title:  Biomicroscopy Scale  
Page 3 of 5 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 129 of 169   
 Document Type:      
Document Number:   Revision Number: 10  
 
 
 
Title:  Biomicroscopy Scale  
Page 4 of 5 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 130 of 169   
 Document Type:      
Document Number:   Revision Number: 10  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Title:  Biomicroscopy Scale  
Page 5 of 5  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 131 of 169   
 Document Type:      
Document Number:   Revision Number: 10  
 
 
 
 
 
 
 
 
 
 
 
 
 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 132 of 169   
 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
KERATOMETRY  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 133 of 169   
 Revision  Number:  03 Title:  Keratometry  Procedure 
Document Type:  
Document Number:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 1 of 1  on 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 134 of 169   
 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
DISTANCE AND NEAR VISUAL ACUITY EVALUATION  
Title:  Distance and Near Snellen Visual Acuity Evaluation  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 135 of 169   
 Document Type:      
Document Number:   Revision Number:  5 
 
 
 
 
 
 
 
 
 
 
 
 
 
Title:  Distance and Near Snellen Visual Acuity Evaluation  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 136 of 169   
 Document Type: 
Document Number:   
Revision Number:  5 
Title:  Distance and Near Snellen Visual Acuity Evaluation  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 137 of 169   
 Document Type:      
Document Number:   Revision Number:  5 
 
 
 
 
 
 
 
 
 
 
 
 
Title:  Distance and Near Snellen Visual Acuity Evaluation  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 138 of 169   
 Document Type:      
Document Number:   Revision Number:  5 
 
 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 139 of 169   
 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
TORIC FIT EVALUATION  
Title:  Toric Fit Evaluation  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 140 of 169   
 Document Type:      
Document Number:   Revision Number:  7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Title:  Toric Fit Evaluation  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 141 of 169   
 Document Type:      
Document Number:   Revision Number:  7 
 
 
Title:  Toric Fit Evaluation  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 142 of 169   
 Document Type:      
Document Number:   Revision Number:  7 
 
 
 
 
 
 
 
 
 
Title:  Toric Fit Evaluation  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 143 of 169   
 Document Type:      
Document Number:   Revision Number:  7 
 
 
 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 144 of 169   
 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
DISTANCE  LOGMAR  VISUAL  ACUITY  MESAUREMENT 
PROCEDURE  
Distance LogMAR   Visual Acuity Measurement  Procedure   Title:  
Page 1 of 3 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 145 of 169   
 Document Type: 
Document Number:     
  Revision Number:  5  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Distance LogMAR   Visual Acuity Measurement  Procedure   
   
  Revision Number:  5  Title:  
Page 2 of 3 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 146 of 169   
  
 
 
 
 Document Type:   
Document Number:    
 
Distance LogMAR   Visual Acuity Measurement  Procedure   
   
  Revision Number:  5  Title:  
Page 3 of 3  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 147 of 169   
  
 
 
 
 
 
 
 
 
 
 
 
 
 Document Type:   
Document Number:    
 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 148 of 169   
 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
VISUAL ACUITY CHART LUMINANCE AND ROOM ILLUMINATION  
TESTING  
Title:  
Document Type: 
Document Number:  Visual Acuity Chart Luminance and Room Illumination Testing  
Revision Number:  4 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 149 of 169   
  
  
 
 
 
 
 
 
Title:  
Document Type: 
Document Number:  Visual Acuity Chart Luminance and Room Illumination Testing  
Revision Number:  4 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 150 of 169   
  
 
Title:  
Document Type: 
Document Number:  Visual Acuity Chart Luminance and Room Illumination Testing  
Revision Number:  4 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 151 of 169   
  
  
 
Title:  
Document Type: 
Document Number:  Visual Acuity Chart Luminance and Room Illumination Testing  
Revision Number:  4 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 152 of 169   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Title:  
Document Type: 
Document Number:  Visual Acuity Chart Luminance and Room Illumination Testing  
Revision Number:  4 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 153 of 169   
  
 
 
 
 
 
Title:  
Document Type: 
Document Number:  Visual Acuity Chart Luminance and Room Illumination Testing  
Revision Number:  4 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 154 of 169   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Title:  
Document Type: 
Document Number:  Visual Acuity Chart Luminance and Room Illumination Testing  
Revision Number:  4 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 155 of 169   
  
 
 
 
 
 
 
Title:  
Document Type: 
Document Number:  Visual Acuity Chart Luminance and Room Illumination Testing  
Revision Number:  4 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 156 of 169   
  
 
 
 
 
 
 
Clinical Study Protocol  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 157 of 169   
 [COMPANY_012] Vision Care, Inc.  
 
APPENDIX H: GUIDELINES FOR COVID -19 RISK MITIGATION  
Title:  Guidelines for CO VID-19 Risk  Mitigation   
   
  Revision Number:  5  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 158 of 169   
  
 
1.0 PURPOSE  
 
The purpose of this document is to provide guidelines for the re -opening or initiation of clinical study sites 
participating in [COMPANY_012] Vision Care, Inc. (JJVCI) clinical studies during the COVID -19 
pandemic.  
 
2.0 SCOPE  
 
This document  provides  guidelines  for Johnson  & Johnson  Vision  Care  (JJVCI)  to address  the potential  risks 
from COVID -[ADDRESS_103912] from th e date of approval through the date of retirement of this Work 
Instruction. At a minimum, this Work Instruction will be reviewed and updated on a quarterly basis, as 
appropriate.  
 
NOTE: Re -opening of sites outside of the US will be evaluated on a country b y country basis subject 
to local health authority guidance.  
 
3.0 DEFINITIONS  
 
American Academy of Optometry (AAO): The American Academy of Optometry is an organization of 
optometrists based in Orlando, [LOCATION_012]. Its goal is to maintain and enhance excellenc e in optometric 
practice, by [CONTACT_93949]. The AAO holds an annual 
meeting, publishes a monthly scientific journal, gives credentials to optometrists through the fellowship 
process and publishes position statem ents. 
 
American Optometric Association (AOA): The American Optometric Association, founded in 1898, is 
the leading authority on quality care and an advocate for our nation's health, representing more than 44,000 
Doctors of Optometry (O.D.), optometric prof essionals, and optometry students. Doctor of Optometry take 
a leading role in patient care with respect to eye and vision care, as well as general health and well -being. 
As primary health care providers, Doctor of Optometry have extensive, ongoing training  to examine, 
diagnose, treat and manage ocular disorders, diseases and injuries and systemic diseases that manifest in the 
eye. The American Optometric Association is a federation of state, student, and armed forces optometric 
associations. Through these a ffiliations, the AOA serves members consisting of optometrists, students of 
optometry, paraoptometric assistants and technicians. The AOA and its affiliates work to provide the public 
with quality vision and eye  care.  
Centers for Disease Control and Prevention (CDC): The Centers for Disease Control and Prevention is a 
national public health institute in the [LOCATION_002]. It is a [LOCATION_002] federal agency, under the 
Department of Health and Human Services, and is hea dquartered in Atlanta, Georgia.  
COVID -19: Current outbreak of respi[INVESTIGATOR_19538] a novel coronavirus. The virus has been 
named “SARS -CoV -2” and the disease it causes has been named “Coronavirus Disease 2019” (COVID - 
19). 
Clinical Study: Voluntar y research studies conducted in people and designed to answer specific questions 
about the safety or effectiveness of drugs, vaccines, other therapi[INVESTIGATOR_014], or new ways of using existing 
treatments. May also be called clinical trials, studies, research, trials,  or protocols.  
Clinical Study Site: Location where a clinical study is conducted, such as a doctor’s office, university, or 
laboratory. Clinical studies are conducted by [CONTACT_35583](s) responsible for the 
conduct of the clinical study at a study site. If a study is conducted by a team of individuals, the 
Investigator is the responsible leader of the team and may be called the Principal Investigator.  
Clinical Operations Manager (COM): The [COMPANY_012] Vision Care (JJVCI) individual 
responsible for the overall management of a clinical trial.  Document Type:   
Document Number:    
 
Title:  Guidelines for CO VID-19 Risk  Mitigation   
   
  Revision Number:  5  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 159 of 169   
  
Monitor: An individual designated to oversee the progress of a clinical study and ensure that it is 
conducted, recorded, and reported in accordance with the protocol, Standard Operating Procedures (SOPs), 
Good Clinical Practice (GCP), and applicable regulatory requ irements.  
 
Medical Safety Officer (MSO): Physician who has primary accountability in their product portfolio for 
product health and safety, and who serves as an independent medical voice for patient safety.  
 
Safety Management Team (SMT): A cross -functional, collaborative team responsible for revi ew, 
assessment and evaluation of medical safety data arising from any source throughout the product life cycle.  
 
4.[ADDRESS_103913]  the health,  safety 
and well -being of participants and site staff. If, at any time, a participant’s safety is considered to be at risk, 
study  intervention  will be discontinued,  and study  follow -up will be conducted  as outlined  in the protocol.  
 
During  the COVID -19 pand emic,  the additional  risks  listed  below  need  to be considered  for study  participants 
and study  personnel:  
 
Additional Risks Related to the COVID -19 Pandemic:  
• The possible transmission of the Coronavirus infection and consequent complications, beyond the 
risk of adverse events due to the investigational device and/or  procedures.  
• The risk may be higher in an optometric clinical study because of the close contact [CONTACT_93950] (since the investigator 
must make the measurements close to the subject’s face) and, in addition the need for multiple 
follow -up visits/exams which may expose the su bject to other patients and/or healthcare 
professionals who might be transmitting the virus, even if they do not have  symptoms.  
• Potential disruptions to the study may be necessary due to current or future pandemic -related 
emergency restrictions, which may lead to delays in scheduled follow -up visits.  
• Subjects experiencing an adverse event related to contact [CONTACT_93951] -[ADDRESS_103914] contracted COVID -19 during participation in a study, he/she will be 
discontinued from the study and followed until COVID -19 Adverse Event (AE) resolution.  
 
To help minimize the above potential risks, JJVCI recommend reviewing/complying with local, state, 
and governmental guidance for COVID -19 risks.  
 
JJVCI will provide the following study specific documents with language pertaining to COVID -19 risks:  
 
4.1.1 Informed Consent : 
 
Will include in formation concerning the study -associated risks related to the COVID -19 pandemic 
in bold font and/or boxed on the first page of the Informed Consent document:  
Document Type:   
Document Number:    
 
Title:  Guidelines for CO VID-19 Risk  Mitigation   
   
  Revision Number:  5  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 160 of 169   
  
STUDY ASSOCIATED RISKS RELATED TO COVID -19 (CORONAVIRUS) PANDEMIC  
 
It is important to note that this study will be conducted, at least in part, during the COVID -[ADDRESS_103915] for yo u. This is particularly important for this 
study due, in part, to the closeness of the doctor during the study examinations.  
 
The potential effects of the disease are not fully known, at this time, and may include long -term serious health 
consequences. In severe cases, this may result in hospi[INVESTIGATOR_5478]/or death. Based on current knowledge from the 
Centers for Disease Control and Prevention (CDC), those at high -risk for severe illness from COVID -19 include 
older adults and people with underlying medical  conditions.  
 
During this study, all appropriate measures will be taken to minimize risks including the use of personal protective 
equipment such as masks and gloves, as well as proper sanitization. This is in conformance to guidance from the 
CDC, local he alth departments, and the state and county in which the study doctor’s office is located. However, 
these measures may not completely eliminate the risks associated with contracting COVID -19. 
 
If you are found to have contracted COVID -19 or feel ill with fl u-like symptoms during participation in the study, 
you will not be permitted to continue in -office study follow -up visits, but you will receive instructions and your 
condition will be monitored by [CONTACT_35586]/or study staff.  
 
4.1.[ADDRESS_103916] (Attachment -B): 
 
Will include COVID -[ADDRESS_103917] JJVCI clinical 
studies. The risk controls are consistent with CDC, AOA, AAO Guidance. The Principal 
Investigator [INVESTIGATOR_5972]/sign the study specific che cklist prior to the Site Initiation Meeting.  
 
 
4.1.3 Protocol Compliance Investigator(s) Signature  [CONTACT_3490]:  
 
Will include a statement indicating that the Principal Investigator (PI) agrees to conduct the study 
in compliance with all local, state, and governmental guidance’s for COVID -[ADDRESS_103918]  read the suggested  guidance  provided  by [CONTACT_93952] -19 risk mitigation, 
(COVID -19 Work Instruction in the Appendix of this protocol). I agree to conduct this study in 
compliance with local, state, governmental guidance for COVID -19 risks.  
 
4.1.4 Study Site Initiation Training  Slides:  
 
Will inclu de suggestions to help mitigate potential transmission of COVID -19. Suggestions may 
include maintaining social distancing in the clinical site by [CONTACT_35587], 
wearing proper PPEs, frequent disinfection, and installing shields on the slit lamp and other 
applicable equipment.  
 
5.[ADDRESS_103919] VISITS  
 
Potential disruptions to the study may be necessary due to current or future pandemic -related emergency 
restrictions. Possible disruption of the study as a result of COV ID-19 control measures may lead to delays 
in scheduled follow -up visits.  
 
Subjects may be delayed in being seen for study follow up visit(s), for example due to COVID -[ADDRESS_103920]’s concerns or fears about COVID -[ADDRESS_103921]  during  remote  assessments 
may include:  Document Type:   
Document Number:    
 
Title:  Guidelines for CO VID-19 Risk  Mitigation   
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 161 of 169   
 Document Type: 
Document Number:     
  Revision Number:  [ADDRESS_103922] article when applicable and feasible.  
Change of Medical History 
(Adverse Events) and 
Concomitant Medications / 
Therapi[INVESTIGATOR_93808]/parents.  
Review the subject’s concomitant medications/therapi[INVESTIGATOR_93809] d record 
any changes from the previous study visit.  
Wearing Time and 
Compliance  Record the average wearing time (including number of hours per day 
during weekdays and weekends, and number of days per week).  
Confirm compliance with the prescribed wear sche dule.  
• Record and discuss the lens wear compliance based on the 
subject’s self -report. For example, the subjects will be asked the 
time of the day the subject typi[INVESTIGATOR_93810], the number of days per w eek 
lenses were worn, and the number of consecutive days the subject 
didn’t wear the study lenses,  etc. 
 
The discussion  with the subject  will be documented  in EDC  under  Tele-Visit  and a minor  protocol  deviation 
will be noted.  If during  the telephone  consultation,  a subject  states  he/she  wishes  to discontinue  participating 
in the study, instruct the subject to stop wearing the study lenses and schedule the subject to return to the 
clinic for a Final Evaluation at the at earliest possible time . Subjects should return all unused lenses to the 
clinic at the last  visit.  
 
Changes in study visit schedules, missed visits, or participant discontinuations may lead to missing data, 
including data related to protocol -specified procedures. Case report for ms should capture specific 
information regarding the basis of missing data, including the relationship to the COVID -[ADDRESS_103923] DURING  PANDEMIC  
 
It is recognized  that the Coronavirus  Disease  2019  (COVID -19) pandemic  may have  an impact  on the conduct 
of this clinical study due to, for example, self -isolation/quarantine by [CONTACT_19611] -site personnel; 
travel restrictions/limited access to public places, including Optometry Clinics; and changes in clinic 
procedures require d to address the COVID -19 challenge.  
 
Every effort should be made to adhere to protocol -specified assessments for study participants, including 
follow -up. However, if scheduled visits cannot be conducted in person at the study site it is suggested that 
assessments be performed to the extent po ssible remotely/virtually or delayed until such time that on -site 
visits can be resumed in order to continue participant monitoring in accordance with the protocol where 
possible. At each contact, participants will be interviewed to collect safety data. Ke y efficacy endpoint 
assessments should be performed if required and as feasible.  
 
Modifications  to protocol -required  assessments  may be permitted  via COVID -19 Appendix  after consultation 
with the participant, investigator, and the sponsor. Missed assessmen ts/visits will be captured in the clinical 
trial management system for protocol deviations. Interruptions of test article wear or discontinuations of 
study interventions and withdrawal from the study should be documented with the prefix “COVID -19- 
related”  in the case report form  (CRF).  
Title:  Guidelines for CO VID-19 Risk  Mitigation   
   
  Revision Number:  [ADDRESS_103924] the sponsor’s responsible 
medical monitor to discuss initial plans for study intervention and follow -up. The medical monitor will 
notify the Safety Management Team of any subject(s) that have reported “COVID -19”, “Asymptomatic 
COVID -19”, or “Suspected COVID -19” adverse events within [ADDRESS_103925] as a result of the COVID -19 pandemic will be summarized in the 
clinical study report.  
 
COVID -19 screening procedures that may be mandat ed by [CONTACT_35588].  
 
Monitoring Visits  
 
When  on-site monitoring  by [CONTACT_93953],  the sponsor’s  site monitor  will contact  [CONTACT_19614]. In such cases, on -site monitoring visits will resume when feasible, with 
increased frequency to address the source data verification  backlog.  
 
Even  with staffing  limitations  during  this COVID -[ADDRESS_103926] process. When conditions permit, all 
parties  involved  in this clinical  trial should  communicate  relevant  information  in a timely  manner  so that 
all relevant parties remain sufficiently  informed.  
 
6.1.1 Study Site  Initiation:  
 
During the period that this Work Instruction is in effect, Site Initiation Meetings and training of 
study site staff will be conducted remotely. The JJVCI study team will con duct training via Skype, 
Zoom,  Microsoft  Teams  or similar  software  as well as utilize  online  training  materials,  as applicable. 
Study  site training  will be documented  utilizing  Site Initiation  Report  
 
On-site visits  may be considered  when,  for example,  hands -on training  or evaluation  of site facilities 
is required. While on site, the Clinical Research Associate (CRA) will follow all local, state, and 
governmental  policies for COVID -19 Risk Mitigation,  including  social  distancing,  wearing  of PPE, 
etc. as applicable for the location of the study  site. 
 
6.1.2 Interim Monitoring Visits (if  applicable):  
 
During the period that this Work Instruction is in effect, Interim Monitoring On -site visits will be 
kept to a minimum  and include  only those  tasks  that the CRA  cannot  perform  remotely  (e.g.,  source 
document verification, test article reconciliation,  etc.). 
 
To ensure  data integrity  during  the conduct  of all JJVC  studies,  clinical  study  teams  will follow  the 
study specific Clinical Monitoring  Plan 
 
While on site, the CRA will follow all local, state, and governmental policies for COVID -19 Risk 
Mitigation, including social distancing, wearing of PPE, etc. as applicable for the location of the 
study site.  
Document Type:   
Document Number:    
 
Title:  Guidelines for CO VID-19 Risk  Mitigation   
   
  Revision Number:  5  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 163 of 169   
  
6.1.3 Study Site  Closure:  
 
During  the period  that this Work  Instruction  is in effect,  the duration  of the Study  Site Closure  Visit 
will be limited to tasks that the CRA cannot perform remotely (e.g., source document verification, 
test article final reconciliation and return,  etc.).  Document Type:   
Document Number:    
 
Title:  Guidelines for CO VID-19 Risk  Mitigation   
   
  Revision Number:  5  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 164 of 169   
  
Attachment A: Study Site Correspondence  
 
XXXX XX, 2020  
 
 
Re: COVID -19 Mitigation Plan, <<CR -xxxx/protocol title>>  
 
 
Dear <<Principal Investigator>> and Study Team,  
 
Coronavirus (COVID -19) has impacted several communities and business activities over the past several months. 
While we work toward the successful conduct of clinical studies, our commitment continues to be the safety of 
patients, healthcare professionals, and to our communities.  
 
Therefore, we would like to share the following revisions/additions related to the above referenced Johnson & 
Johnson Vision Care company sponsored clinical trial(s) you are currently working on or considering participation 
within.  
 
Protocol:  
 
• Guidelines for COVID -19 Risk Mitigation provided in the Appendix  section.  
 
Protocol Signature [CONTACT_3490]:  
 
• Will include a statement indicating the Principal Investigator [INVESTIGATOR_93811], state, and governmental guidelines for COVID -19 risk  mitigation.  
 
Informed Consent:  
 
• Will include information concerning the study -associated risks related to the COVID -19 pandemic in bold 
font and/or boxed on the first page of the Informed consent  document.  
 
COVID -[ADDRESS_103927] for Clinical Studies:  
 
• Will include  COVID -[ADDRESS_103928] with your respective 
[COMPANY_012] clinical study  team (Clinical Research Associate (CRA), Lead CRA or Study Managers).  
 
Thank you for your continued engagement, collaboration, and dedication to your study subjects during this 
challenging time.  
 
 
Please file this letter in your site file study correspond ence.  Document Type:   
Document Number:    
 
Title:  
Document Type: 
Document Number:  Guidelines for CO VID-19 Risk  Mitigation   
   
  Revision Number:  [ADDRESS_103929] (Attachment -B): 
 
 
Study Number 
Site Number  
Principal Investigator (PI) Name  
 
[CONTACT_35597] -[ADDRESS_103930] [COMPANY_012] Vison Care clinical 
studies. Please review the following requirements and Initial each requirement.  
 
PI [INVESTIGATOR_93812] (waiting rooms, lobby, exam rooms, etc.)  
 Non-contact [CONTACT_93954] -specific training on PPE and demonstrate competency with selection and 
proper use of PPE and wear at all times during interactions with subjects (e.g., putting on and 
removing without self -contamination)  
 
 
PI [INVESTIGATOR_93813] D aily Safety Measures  
 As part of routine practice, site staff should regularly monitor themselves for fever and symptoms 
of COVID -19, including temperature checks  
 Any staff member (including non -study clinic staff and Investigators) showing signs of being sick 
or testing positive for COVID -[ADDRESS_103931] and the Sponsor shall be informed  
NOTE: Inform JJVC in [ADDRESS_103932] 20 seconds or use an alcohol -based hand sanitizer 
when they arrive, before and after each patient, before eating and after using the bathroom.  
 Cleaning and disinfection procedures for exam rooms and instrumen ts or equipment between 
patients with gloves.  
 Cleaning and disinfection procedures for commonly touched surfaces (doors, chairs, computers,  
phones, etc.) with gloves.  
 
 
PI [INVESTIGATOR_93814] a Patient or Study Visit:  
 Patients should be asked prior to entering the site about fever and respi[INVESTIGATOR_93815] a family member have had contact [CONTACT_35590] -[ADDRESS_103933] patients that companions should remain outside of the facility and not accompany the 
patient into the facility unless they are a parent/guardian of the patient or if they are a true  
caregiver and need to assist the patient  
 Request the patient to call or text the office upon arrival so entrance to and movement through 
facility can be coordinated by [CONTACT_93955]:  
Document Type: 
Document Number:  Guidelines for CO VID-19 Risk  Mitigation   
   
  Revision Number:  5  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 166 of 169   
  
PI [INVESTIGATOR_93816]:  
 Temperature checks utilizing a non -contact [CONTACT_93956].  
 All patients and companions must wear cloth or disposable mask at all times in the site  
 Maintain social distancing. Waiting rooms or lobbies should be as empty as possible. Advise 
seated patients to remain at least 6 feet from one another.  
 Communal objects in (e.g. toys, reading materials, etc.) should be removed or cleaned regularly.  
 
 
 
I certify that I have read and agree to implement all the listed COVID -[ADDRESS_103934] of [COMPANY_012] Vision Care s tudies.  
 
 
 
 
 
 
 
Principal Investigator [INVESTIGATOR_93817]:  Guidelines for CO VID-19 Risk  Mitigation   
   
  Revision Number:  5  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 167 of 169   
  
RESOURCE LINKS  
 
US Resource Links  
 
• OSHA  Training  
https://www.o sha.gov/SLTC/covid -19/controlprevention.html  
 
Personal Protective Equipment (PPE) Training  
CDC: https://www.cd c.gov/cor onavirus/2019 -ncov/hcp/using -ppe.html  
 
• I&R Training  
ACUVUE® LensAssist: https: //www.acuvue.com/len sassist  
 
• Clinic Preparedness  Guides  
CDC: https://www.cd c.gov/coron avirus/2019 -ncov/hcp/clinic -preparedness.html  
AOA: https://aoa.uberflip.com/i/1240437 -aoa-guidance -for-re-opening -practices -covidꞏ19/1?m4=  
American Optometric Association: https:// www.aoa.org/optometry -practice -reactivation -preparedness - 
guide  
 
• ln-Office Disinfection of Multi -Patient Use Diagnostic Contact  [CONTACT_93957]://www.gpli.in fo/wp-content/uplo ads/2020/03/20 20-01-15-in-office -disinfecting -of-diagnostic - 
lenses.pdf  
 
OUS Resource Links  
 
• Updates on local regulations in Hong Kong  
https://www.coron avirus.gov.hk/eng/index.html  
 
• Resumption of optical services in England: Letter from Matt Neligan and Poonam Sharma  
https://www.eng land.nhs.uk/coronavirus/wp -content/uploads/sites/52/2020/04/C0601 -reopening -of-optical - 
services -letter -17-june-2020.pdf  
 
• NHS Optical  Letter  
https://www.eng land.nhs.uk/coronavirus /wp-content/uploads/sites/52/2020/04/C0127 -optical -letter -1-april- 
2020.pdf  
 
• The College of Optometrists primary eye care COVID -19 guidance: Red  phase  
https://www.colleg e-optometrists.org/the -college/media -hub/news -listing/coronavirus -covid -19-guidance - 
for-optometrists.html  
 
• The College of Optometrists COVID -19: College  updates  
https://www.colleg e-optometrists.org/the -college/media -hub/news -listing/coronavirus -2019 -advice -for- 
optometrists.html#CollegeGuidelines  
 
• Infection Control Guidelines. (n.d.). Retrieved from Canadian Association Of Optometrists: 
https://opto.ca/sites/de fault/files/resources/documents/infection_control_guidelines_2016.pdf  
• Infection prevention and control for COVID -19: Interim guidance for outpatient and ambulatory care 
settings.  (2020,  May 23 May).  Retrieved  from  Government  of Canada:  https://www.can ada.ca/en /public - 
health/services/diseases/2019 -novel -coronavirus -infection/guidance -documents/interim -guidance - 
outpatient -ambulatory -care-settings.html  Document Type:   
Document Number:    
 
Title:  Guidelines for CO VID-19 Risk  Mitigation   
   
  Revision Number:  5  
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 168 of 169   
  
• Information for Members On Coronavirus (COVID -19). (n.d.). Retrieved from Canadian Association Of 
Optometrists: 
https://opto.ca/sites/default/files/resources/documents/information_for_members_on_coronavirus.pdf  
• Coronavirus (COVID -19) resources for health p rofessionals, including aged care providers, pathology 
providers and health care managers. (2020, September 24). Retrieved from Australian Government 
Department of  Health:  
https://www.health .gov.au/resources/collections/coronavirus -covid -19-resources -for-health -professionals - 
including -aged -care-providers -pathology -providers -and-health -care-managers  
 
• Environmental Cleaning and Disinfection Principles for COVID -19. (n.d.). Retrieved from Australian 
Government Department of Health: 
https://w ww.h ealth.gov.au/sites/default/files/d ocuments/2020/03/environmental -cleaning -and-disinfection - 
principles -for-covid -19.pdf  
• Infection control guidelines and advice. (n.d.). Retrieved from Optometry Australia : 
https://www.op tometry.org.au /practice -professional -support/coronavirus -covid -19-what -optometrists -need- 
to-know/covid -19-clinical -advice/infection -control -guidelines -and-advice/  Document Type:   
Document Number:    
 
CR-6383, v 4.0  JJVC CONFIDENTIAL  
Page 169 of 169   
 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
PROTOCOL COMPLIANCE INVESTIGATOR(S) SIGNATURE [CONTACT_93962]: CR -[ADDRESS_103935] Lens  
 
Version and Date: 4.0, [ADDRESS_103936] this study according to ISO [ZIP_CODE] :2020,1 GCP and ICH guidelines ,2 the 
Declaration of  Helsinki ,3 [LOCATION_002] (US) Code of Federal Regulations (CFR) ,4 and the 
pertinent individual country laws/regulations and to comply with its obligations, subject to 
ethical  and safety  considerations.  The Principal  Investigator  [INVESTIGATOR_93818], including Sub -Investigators adhere to all ICH2 regulations and GCP 
guidelines regarding clinical trials during and afte r study  completion.  
 
I will assure that no deviation from or changes to the protocol will take place without prior 
agreement from the Sponsor and documented approval from the Institutional Review Board 
(IRB), except where necessary to eliminate an immediat e hazard(s) to the trial participants.  
 
I am responsible  for ensuring  that all clinical  site personnel  including  Sub-Investigators  adhere 
to all ICH2 regulations and GCP guidelines regarding clinical trials during and after study 
completion.  
 
All clinical site personnel involved in the conduct of this study have completed Human 
Subjects Protection Training.  
 
I agree to ensure that all clinical site personnel involved in the conduct of this study are 
informed about their obligations in meeting the above commitments.  
 
I shall not disclose the information contained in this protocol or any results obtained from  this 
study without written  authorization.  
 
Principal  
Investigator:       
[INVESTIGATOR_93819] (Printed)  
 
Institution/Site:     
Institution/Site  Name  
 
 
[CONTACT_16277]/Site Address  